Exercise training for chronic heart failure (ExTraMATCH II): individual participant data meta-analysis of randomised controlled trials by Taylor, R et al.
1 
 
Exercise Training for Chronic Heart Failure (ExTraMATCH II): 
Individual participant data meta-analysis of randomised 
controlled trials 
 
Keywords: 
Heart failure, meta-analysis, cardiac rehabilitation, randomised controlled trials, surrogate 
outcomes 
 
Authors Affiliation: 
Prof Rod Taylor (Chief Investigator) - University of Exeter Medical School and University of 
Glasgow, UK  
Dr Sarah Walker - University of Exeter Medical School, UK  
Dr Oriana Ciani - University of Exeter Medical School, UK and Centre for Research on 
Health and Social Care Management, Bocconi University, Milan, Italy 
Dr Fiona C Warren - University of Exeter Medical School, UK  
Professor Neil A Smart - University of New England, Australia  
Professor Massimo Piepoli –Guglielmo da Saliceto Hospital, Italy  
Associate Professor Constantinos H Davos – Academy of Athens, Greece 
 
Corresponding author: 
Professor Rod Taylor, Institute of Health Research, University of Exeter Medical School, 
College of Medicine and Health, College House, St Lukes Campus, Heavitree Road, Exeter, 
EX1 2LU, England, United Kingdom. Email: r.taylor@exeter.ac.uk Tel: +44 (0)7968 152537 
 
Conflicts of interest: 
Taylor is currently co-chief investigator on a National Institute for Health Research (NIHR) 
funded programme grant designing and evaluating the clinical and cost-effectiveness of a 
home-based cardiac rehabilitation intervention for heart failure patients (RP-PG-1210-
12004). He is also a member of NIHR Priority Research Advisory Methodology Group 
(PRAMG), August 2015-present. Previous roles include: NIHR South West Research for 
Patient Benefit (RfPB) Committee South West, 2010-2014; Core group of Methodological 
2 
 
Experts for the NIHR Programme Grants for Applied Research programme, 2013-October 
2017; NIHR HTA Themed Call Board, 2012-2014; NIHR HTA General Board, 2014- June 
2017 and Chair of NIHR Health Services and Delivery Research Researcher-Led panel, 
March 2014-Feb 2018. All other authors declare no conflicts. 
 
Abstract  
(Word count 555) 
 
Background: Current national and international guidelines on the management of heart 
failure (HF) recommend exercise-based cardiac rehabilitation (ExCR), but do not 
differentiate this recommendation according to patient subgroups. 
 
Objective(s):  (1) to obtain definitive estimates of the impact of ExCR interventions versus 
control (no exercise intervention) on mortality, hospitalisation, exercise capacity, and health-
related quality of life (HRQoL) in HF patients; (2) to determine the differential (subgroup) 
effects of ExCR in HF patients according to their age, gender, ejection fraction, aetiology, 
New York Heart Association (NYHA) class, and baseline exercise capacity; (3) to assess 
whether the change in exercise capacity mediates for the impact of the ExCR on final 
outcomes (mortality, hospitalisation, and HRQoL) and is an acceptable surrogate endpoint. 
 
Design: Individual participant data (IPD) meta-analysis 
 
Setting: An international literature review 
 
Participants: HF patients in randomised controlled trials (RCTs) of ExCR   
 
Interventions: ExCR for at least 3 weeks compared with no exercise control with 6 months 
follow-up 
 
Main outcome measures: mortality (all cause and HF-specific), hospitalisation (all-cause & 
HF-specific), exercise capacity, and HRQoL 
 
Data sources: Individual participant data from eligible RCTs  
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Review methods: RCTs from ExTraMATCH IPD meta-analysis and 2014 Cochrane 
systematic review of ExCR  
 
Results: Out of the 23 eligible RCTs (4,398 patients), 19 RCTs (3,990 patients) contributed 
data to this IPD meta-analysis. There was a wide variation in exercise programme 
prescriptions across included studies. Compared with control, there was no statistically 
significant difference in pooled time to event estimates in favour of ExCR although 
confidence intervals were wide: all-cause mortality: hazard ratio (HR) 0.83 (95% confidence 
interval (CI): 0.67 to 1.04), HF-related mortality: HR 0.84 (95% CI: 0.49 to 1.46), all-cause 
hospitalisation: HR 0.90 (95% CI: 0.76 to 1.06), and HF-related hospitalisation: HR 0.98 
(95% CI: 0.72 to 1.35). There was a statistically significant difference in favour of ExCR for 
exercise capacity and HRQoL. Compared to control, at 12-months follow-up, improvements 
were seen in the six-minute walk test (6MWT) (mean: 21.0 metres, 95% CI: 1.57 to 40.4, and 
Minnesota Living with HF Questionnaire score (mean: -5.94, 95% CI: -1.0 to -10.9, lower 
scores indicate improved HRQoL). No strong evidence for differential intervention effects 
across patient characteristics was found for any outcomes. Moderate to good levels of 
correlation (R2 trial>50% & ρ>0.50) between peak oxygen uptake (VO2peak) or 6MWT with 
mortality and HRQoL were seen. Estimated surrogate threshold effect (STE) was an increase 
of 1.6 to 4.6 ml/kg/min for VO2peak.  
 
Limitations: Lack consistency in how included RCTs defined and collected the outcomes; 
we were unable to obtain IPD from all includable trials for all outcomes; and we did not seek 
patient level on exercise adherence. .  
 
Conclusions: In comparison to no exercise control, participation in ExCR improves the 
exercise and HRQoL in HF patients but appears to have no effect on their mortality or 
hospitalisation.  No strong evidence was found of differential intervention effects of ExCR 
across patient characteristics. VO2peak and 6MWT may be suitable surrogate endpoints for 
the treatment effect of ExCR on mortality and HRQoL in HF.  
* 
4 
 
Future work: Consensus on definition, collection, and reporting of core sets of outcome data 
future ExCR RCTs in HF; continuance of policies that encourage RCTs authors to make their 
datasets available. 
 
Study registration: This study is registered as PROSPERO number CRD42014007170 
 
Funding details: This project was funded by the NIHR Health Technology Assessment 
programme (HTA 15/80/30) 
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Plain English summary  
Exercise-based cardiac rehabilitation is currently recommended in both UK and international 
clinical guidelines for people with heart failure. However, it is remains uncertain whether the 
effects of cardiac rehabilitation are consistent across patient subgroups (e.g. men versus 
women). We sought to review available scientific evidence using individual patient data in 
order to look at this issue.  
 
We searched electronic literature databases for published studies and sought anonymised 
individual patient data from the researchers who conducted these research studies. We were 
able to bring together data from some 3,900 people with heart failure. 
 
Although our analyses of this data show that participation in exercise-based cardiac 
rehabilitation does not appear to impact on the risk of death or hospitalisation, participation 
does offer some improvement in the physical fitness and quality of life of people with heart 
failure. We also found that these benefits were irrespective of patient’s age, gender, ethnicity, 
initial level of physical fitness, or disease severity.  
 
Scientific summary  
Background 
People with symptomatic heart failure (HF) are living for longer following the onset of their 
condition, increasing the importance of effective and accessible services for these patients. 
Exercise-based cardiac rehabilitation (ExCR) is recognised as integral to the comprehensive 
care of HF patients. ExCR is a process by which patients, in partnership with health 
professionals, are encouraged and supported to achieve and maintain optimal physical health. 
Current national and international guidelines on the management of HF recommend ExCR, 
but do not differentiate according to patient subgroups. 
 
Objectives 
The Exercise Training Meta-Analysis of Trials for Chronic Heart Failure (ExTraMATCH II) 
project aimed to determine which HF patient subgroups benefit most from ExCR using 
individual participant data (IPD) meta-analysis.  
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The project had three objectives. 
1. To obtain definitive estimates of the impact of ExCR interventions versus control (no 
exercise intervention) on mortality, hospitalisation, exercise capacity, and health-
related quality of life (HRQoL) in HF patients. 
2. To determine the differential (subgroup) effects of ExCR in HF patients according to 
their: (i) age, (ii) gender, (iii) left ventricular ejection fraction, (iv) HF aetiology, (v) 
New York Heart Association (NYHA) class, and (vi) baseline exercise capacity. 
3. To assess whether the change in patient exercise capacity mediates and is an 
acceptable surrogate endpoint for the impact of the ExCR on final outcomes 
(mortality, hospitalisation, and HRQoL).  
The information gained from the ExTraMATCH II project will inform future UK and 
international clinical and policy decision-making on the use of ExCR in HF. 
 
Methods  
We conducted and reported this study in accordance the Preferred Reporting Items for a 
Systematic Review and Meta-analysis of Individual Participant Data (PRISMA IPD) 
statement. Randomised controlled trials were identified from the original ExTraMATCH IPD 
meta-analysis and the 2014 Cochrane systematic review of ExCR for HF; these were based 
on searches of the following electronic databases: Cochrane Central Register of Controlled 
Trials (CENTRAL) in The Cochrane Library, EMBASE, MEDLINE, CINAHL, PsycINFO, 
and the NHS Centre for Reviews and Dissemination. Conference proceedings and trial 
registers were also searched. In keeping with the original ExTraMATCH IPD meta-analysis, 
trials of exercise training for at least 3 weeks compared with no exercise control with 6 
months’ follow-up or longer were included if they provided IPD on mortality or 
hospitalisation (all-cause or HF-specific) time to event or exercise capacity or HRQoL. The 
datasets of IPD were combined into a single dataset. One-stage fixed effect meta-analyses of 
time-to-event endpoints were performed using Cox proportional hazards models, stratified by 
study. One-stage meta-analyses of continuous outcomes were performed using hierarchical 
linear models with adjustments for baseline values and a random effect on study. Two-stage 
models using fixed and random effects were also performed. Interactions terms between 
ExCR and participant characteristics were used to assess potential differential effects of 
ExCR across subgroups. Mediational analyses and meta-analytic regressions, with estimation 
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of R2 at the trial level, and surrogate threshold effect (STE) were performed to assess the 
question of surrogate validity for exercise capacity outcomes of peak oxygen uptake 
(VO2peak) and six minute walk test (6MWT). 
 
Results 
Of the 23 eligible trials (4398 patients), 19 trials contributed data to the IPD meta-analysis – 
18 trials (3912 patients) to the clinical events (mortality and hospitalisation) analysis, 13 trials 
(3332 patients) to exercise capacity and HRQoL analysis, and 10 trials (2656 patients) to the 
exercise capacity mediational/surrogate endpoint analysis. 
 
Characteristics and quality of included trials 
Patient characteristics at baseline were well balanced between ExCR and control group 
patients. The majority of patients were male (75%), with a mean age of 61 years and 
predominantly with reduced ejection fraction HF (HFrEF) (mean baseline left-ventricular 
ejection fraction 26.7% no included trials recruited patients with preserved ejection fraction 
heart failure - ejection fraction >45%), and most patients were in NYHA functional class II 
(59%) or III (37%).  Trials were from Europe and North America and were published 
between 1990 and 2012. Sample size ranged from 50 to 2130 patients. All trials evaluated an 
aerobic exercise intervention, which was most commonly delivered in either an exclusively 
centre-based setting or a centre-based setting in combination with some home exercise 
sessions. The dose of exercise training ranged widely across trials. ExCR was delivered over 
a period of 12 to 90 weeks, with between 2 and 7 sessions per week; median session duration 
was between 15 and 120 minutes (including warm-up and cool-down). The intensity of 
exercise ranged between 50 to 85% peak VO2. The overall quality of included trials was 
judged to be moderate to good, with a median TESTEX score of 11 (range 9 to 14) out of a 
maximum score of 15.   
 
Impact of ExCR on mortality and hospitalisation 
Compared with control, there was no statistically significant difference in pooled time to 
event estimates in favour of ExCR although confidence intervals were wide: all-cause 
mortality: hazard ratio (HR): 0.83 (95% confidence interval (CI): 0.67 to 1.04), HF-related 
mortality: HR 0.84 (95% CI: 0.49 to 1.46), all-cause hospitalisation: HR 0.90 (95% CI: 0.76 
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to 1.06), and HF-related hospitalisation: HR 0.98 (95% CI: 0.72 to 1.35). No strong evidence 
for differential intervention effects across patient characteristics was found. 
 
Impact of ExCR on exercise capacity and HRQoL 
Compared with control, there was a statistically significant difference in favour of ExCR for 
exercise capacity and HRQoL. For example, at 12-month follow-up, improvements were seen 
in the 6MWT (mean: 21.0 metres, 95% CI: 1.57 to 40.4, p=0.034, τ2 = 491, I2 =78%) and 
Minnesota Living with HF Questionnaire score (mean: -5.94, 95% CI -1.0 to -10.9, p=0.018, 
τ2 =77, I2 =88%; lower scores indicate improved HRQoL). No strong evidence for 
differential intervention effects across patient characteristics was found. 
 
Validation of exercise capacity as a surrogate endpoint 
Moderate to good levels of correlation (R2 trial>50% and ρ>0.50) between exercise capacity 
VO2peak or 6MWT with mortality and HRQoL were seen. Estimated STE was an increase of 
1.6 to 4.6 ml/kg/min for VO2peak. Our results indicate that an increase in VO2peak or 6MWT 
with ExCR to be potentially weak mediators of final outcomes. 
 
Discussion 
In HFrEF patients ExCR did not have a statistically significant effect on the risk of mortality 
and hospitalisation. However, uncertainty around effect estimates and lack of individual 
patient data on exercise adherence precludes drawing definitive conclusions in these event 
outcomes. ExCR significantly improves exercise capacity and HRQoL. We found no 
consistent differences in ExCR effects across patient subgroups.  Our results provide 
indicative evidence that VO2peak and 6MWT may be suitable surrogate endpoints for the 
treatment effect of ExCR on final outcomes in HF.  
 
Recommendations for further research 
Two central aspects of future data collection include: a consensus on the definition, 
collection, and reporting of core sets of outcome data, concomitant disease/comorbidities and 
metrics of therapy delivery/uptake plus the capture of data on patient level adherence to the 
amount of exercise training during the ExCR intervention period. More generally, the 
research community should continue to implement policies that encourage primary study 
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authors to make their datasets available, either by depositing in publicly available repositories 
or shared with IPD meta-analysis collaborations when directly requested. 
 
Study registration 
This study is registered as PROSPERO number CRD42014007170. 
 
Funding 
Funding for this study was provided by the Health Technology Assessment programme of the 
National Institute for Health Research (HTA 15/80/30).  
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Chapter 1: Background 
 
Chronic heart failure (HF) is a burgeoning global health challenge that affects 1–2% of adults 
in the western world. (1) While survival after HF diagnosis has improved, prognosis is poor - 
30 to 40% of patients die within a year of diagnosis. (2) Patients with HF experience 
limitations to their exercise capacity, activities of daily living, and health-related quality of 
life (HRQoL) and an increased risk of hospital admission rate and all-cause mortality. (3, 4)  
The cost of management of HF in the UK National Health Service (NHS) was reported to be 
approximately £1 billion in 2010. (5) According to the Office of National Statistics, the 
proportion of the UK population aged 85 and over is projected to double between 2016 and 
2041. (6) Due to increases in both the incidence and prevalence in heart failure with increasing 
age, (7) more demands will be placed on the NHS in this time frame. An increase in the 
prevalence of comorbidities in an older population will lead to a greater number of 
hospitalisations in heart failure patients. (8) 
 
With increasing numbers of people living longer with symptomatic HF, the effectiveness and 
accessibility of health services for HF patients have never been more important. Exercise-
based cardiac rehabilitation (ExCR) is recognised as integral to the comprehensive care of HF 
patients. Cardiac rehabilitation is a process by which patients, in partnership with health 
professionals, are encouraged and supported to achieve and maintain optimal physical health. 
(9) Whilst exercise training is at the centre of cardiac rehabilitation, it is accepted that 
programmes should be comprehensive in nature and include education and psychological 
input focusing on health and life-style behaviour change and psychosocial well-being. (2-4, 9)  
 
Previous systematic reviews and meta-analyses have shown exercise-based rehabilitation 
offers important health benefits for patients. (9-12) Including 33 trials across 4740 HF patients, 
the 2014 Cochrane review (10) shows: no difference in pooled all-cause mortality with ExCR 
(relative risk: 0.93; 95% CI 0.69 to 1.27), reduced risk of overall hospitalisation (relative risk: 
0.75; 95% CI: 0.62 to 0.92) and HF-specific hospitalisation (relative risk: 0.61; 95% CI: 0.46 
to 0.80); and a clinically important improvement in disease-specific health-related quality of 
life (HRQoL) on the Minnesota Living with Heart Failure (MLHFQ) questionnaire (mean 
difference: -5.8 points, 95% CI: -9.2 to -2.4). ExCR for HF is therefore recommended by the 
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National Institute of Health and Care Excellence (NICE) (3) and is a class I recommendation 
of the joint American College of Cardiology Foundation and the American Heart Association 
and the European Society of Cardiology guidelines. (13-15) These guidelines do not 
differentiate by patient subgroup but, rather, recommend CR to all HF patients ‘who are able 
to participate to improve functional status’. (13)  
 
Despite this evidence and recommendation by clinical guidelines, the uptake of ExCR for HF 
remains poor. Only 16% of UK CR centres have a specific rehabilitation programme for HF. 
(16) The recent ExtraHF survey reported that only 40% of centres from across 42 European 
countries implemented an exercise programme for HF.,. (17) Cardiac rehabilitation centres 
report lack of resources to the major barrier to providing rehabilitation services for HF, i.e., 
lack of finances, staff, and equipment. (16, 17) A key potential solution (if supported by 
evidence) could be targeting exercise-based rehabilitation services to those HF patients who 
might experience the greatest benefit in outcomes. Such a differential effect of treatment 
across HF patients could improve the overall clinical and cost-effectiveness of rehabilitation 
for HF and drive improvements in patient uptake of rehabilitation.  
 
Although meta-analyses demonstrate important health benefits with ExCR, there is 
uncertainty whether there are differential effects across HF patient subgroups. Three data 
sources currently provide evidence on this issue but have weaknesses. First, in 2004, the 
Exercise Training Meta-Analysis of Trials in Heart Failure (ExTraMATCH) Collaborative 
Group published an individual participant data (IPD) meta-analysis based on 9 randomised 
trials in 801 HF patients, showing Ex CR reduced all-cause mortality (hazard ratio 0.65, 95% 
CI:, 0.46 to 0.92) and there were no subgroup (age, gender, HF aetiology, New York Heart 
Association (NYHA) class, ejection fraction, or exercise capacity) effects. (18) Given the 
small number of trials, patients, and events (193 deaths) these subgroup analyses are likely to 
be underpowered. Furthermore, a number of trials have been published since, including HF-
ACTION, a large US National Institute of Health funded randomised trial (2331 HF patients 
across 82 centres). (19) Second, the original analysis of the HF-ACTION trial found no 
interactions between treatment allocation (ExCR or no exercise control) and patient 
characteristics (age, gender, HF aetiology, NHYA class, ejection fraction, or depression 
score) for the composite outcome of mortality or hospital admission. (19) Although the largest 
ExCR trial to date, the power of this study to detect small subgroup effects remains limited. 
19 
 
Finally, meta-regression analysis in the 2014 Cochrane review found no association between 
trial level patient characteristics (age, gender, ejection fraction) and the impact of ExCR. (10) 
However, such analysis is highly prone to study level confounding (ecological fallacy) and 
should be interpreted with great caution. The methodology of IPD meta-analysis allows more 
robust analysis of treatment effects in subgroups and consistent analysis of outcome data 
across trials, such as enabling time to event data analyses adjusted for baseline covariates. 
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 Chapter 2: Aims and objectives 
 
The Exercise Training Meta-Analysis of Trials for Chronic Heart Failure (ExTraMATCH II) 
project aimed to determine which HF patient subgroups benefit most from ExCR using IPD 
meta-analysis.  
 
The project objectives were:  
 
1. To obtain definitive estimates of the impact of ExCR interventions versus control (no 
exercise intervention) on all-cause mortality, hospitalisation, HRQoL and exercise 
capacity in HF patients 
 
2. To determine the differential (sub-group) effects of exercise-based interventions in 
HF patients according to their (i) age, (ii) gender, (iii) left ventricular ejection 
fraction, (iv) HF aetiology, (v) NYHA class, and (vi) baseline exercise capacity 
 
3. To assess whether the change in patient exercise capacity mediates and acts as a 
surrogate endpoint for the impact of the ExCR on all-cause mortality, all-cause 
hospitalisation, and disease-specific health-related quality of life.  
 
The information gained from the ExTraMATCH II project will inform future national and 
international clinical and policy decision-making on the use of ExCR in HF. 
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Chapter 3: Methods 
This project was undertaken and reported according to current reporting guidelines for 
individual patient data meta-analyses (20-22) and was registered with PROSPERO 
(CRD42014007170). (23) The project management committees are listed in Appendix 1Error! 
Reference source not found..  
 
Identification of trials for inclusion 
Trials for were identified from ExTraMATCH IPD meta-analysis and the 2014 Cochrane 
systematic review of ExCR for HF. (10, 18) The Cochrane review searched (to January 2013) 
the following electronic databases: Cochrane Central Register of Controlled Trials 
(CENTRAL) in The Cochrane Library, EMBASE, MEDLINE, CINAHL, PsycINFO, and the 
NHS Centre for Reviews and Dissemination (CRD); search strategy is included in Appendix 
2. Conference Proceedings were searched on Web of Science. Trial registers (Controlled-
trials.com and Clinicaltrials.gov) and reference lists of all eligible trials and identified 
systematic reviews were also checked. No language limitations were imposed. Details of the 
search strategy used are reported elsewhere (23) and are included in Appendix 1Error! 
Reference source not found..  
 
Trials were included with if they met the following criteria:  
1. Study design: Randomised controlled trials (RCTs) with a follow-up period of 6 
months or more (in accord with the 2014 Cochrane review) 
2. Target population: Adult patients, aged 18 years and over, with a diagnosis of HF 
with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction 
(HFpEF), based on objective assessment of left ventricular ejection fraction and on 
clinical findings 
3. Setting / context: Patients managed in any setting i.e. hospital, community facility or 
patient’s home 
4. ExCR intervention: An ExCR intervention that included at least an aerobic exercise 
training component performed by the lower limbs, lasting a minimum of 3 weeks, 
(24) either alone or as part of a comprehensive cardiac rehabilitation programme 
which may also include health education and/or a psychological intervention 
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5. Comparator: A non-exercise group receiving standard medical care or an attention 
placebo 
6. Sample size: A sample size of more than 50, to ensure that the logistical effort in 
obtaining, cleaning and organising the data were commensurate with the contribution 
of the data set to the analysis. (25, 26) 
 
Identified randomised controlled trials meeting the inclusion criteria are shown in Appendix 
3Error! Reference source not found.. Study selection for the 2014 Cochrane review and 
ExTraMATCH IPD meta-analysis was performed by the original research teams who 
performed these studies. For the purposes of this project, a single researcher (RST) compared 
the included studies from these two previous studies and applied the above inclusion criteria.  
 
Investigator requests 
The principal investigators of eligible studies were invited (Collaboration InvitationError! 
Reference source not found.) to participate in this IPD meta-analysis and share their 
anonymised trial data. The list of variables which principal investigators were asked to 
provide was reported in the study protocol (27) (see Appendix 4). 
 
Exclusion of trials from IPD analysis 
Trials were excluded if: 
1. They did not respond to the invitation to provide IPD for the ExTraMATCH II 
analysis in spite of repeated contacts attempts being made 
2. They were unable to provide IPD, either because the data had been lost or destroyed 
3. There were patients included in the trial who may also have appeared in another IPD 
dataset  
 
Ethical approval 
The ethics of obtaining data were carefully considered and advice sought from the Health and 
Social Care Information Centre (HSCIC), dated April 2016. The original trials had each 
obtained ethical/Institutional Review Board committee approval and obtained individual 
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patient consent. Given the fully anonymised nature of all the trial datasets (i.e. no inclusion of 
data such as patient name or date of birth, that would allow individual patients to be 
identified), HSCIC confirmed that there was no further legal/ethical or contractual 
requirements for use of this data for the purpose of this project. A revision of HF-ACTION 
(19) data were obtained via the NIH data portal which required that we obtained a letter of 
approval from the University of Exeter Medical School Research Ethics Committee, dated 
13th November 2017 (Ethical Approval).  
 
Data management 
Data files were received in a variety of formats, depending on the security concerns of the 
host institutions. In most cases data transfer was by email of password protected file with a 
separate email containing the password. Each raw data file was saved in its original format on 
receipt and then converted to a Stata file. Data cleaning was carried out in each 
pseudonymised dataset prior to being combined in a master dataset. Within the individual 
datasets, data for each variable (at the patient level) was checked for accuracy in: range; 
extreme values; internal consistency; missing values, and consistency with published reports. 
Data discrepancies or missing information was discussed with trial investigators and 
corrected where appropriate.  
 
All data files were stored on a secure password protected computer server managed and in 
accordance with the data management standard operating procedures of the UK Clinical 
Research Collaboration (UKCRC) registered Exeter Clinical Trials Unit. Access to data at all 
stages of cleaning and analysis was restricted to core members of the research team (OC, 
RST, FCW, and SW). 
 
Patient and Public Involvement (PPI)  
As part of the NIHR Programme Grant (Rehabilitation Enablement in Chronic Heart Failure - 
REACH-HF, PGfAR RP-PG-0611-12004), a PPI Group was established in 2009, consisting 
of eight active members (5 with lived experience of heart failure and 3 patient carer givers). 
The PPI Group are familiar with our ongoing portfolio of Cochrane systematic reviews in 
cardiac rehabilitation.  
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This IPD meta-analysis was proposed to the PPI group meeting in Truro on 1st Nov 2015 
where views were sought on our proposed research questions. Following receipt of funding 
from the National Institute of Health Research (NIHR), the ExTraMATCH II project was 
presented to the PPI group at a further meeting, held in March 2017. Members of the group 
gave views on how the results should be best presented and disseminated to patients, care-
givers and clinicians in order to impact on clinical practice and patient understanding of heart 
failure. Kevin Paul (PPI Group Chair) was a co-applicant for the REACH-HF study and was 
also a member of the REACH-HF Programme Steering Committee. Kevin is a core colleague 
and valued member of our team. He has agreed to act as conduit between the Project 
Advisory Group for ExTraMATCH II and our established PPI Group. The PPI group were 
asked to contribute to, and give views on: (i) the ExTraMATCH II protocol (e.g. whether we 
have prioritised the appropriate outcomes); (ii) lay summaries of the ExTraMATCH II 
project; (iii) the implications for clinical practice and future research; and (iv) the planned 
dissemination strategy. 
 
Kevin commented on the plain English summary of the original application and also offered 
advice on the Plain English Summary of this document. Based on the INVOLVE guidelines, 
(28) we included the cost of his time to attend Project Advisory Group meetings, plus his 
travel.  
 
Statistical analysis 
All analyses were carried out according to the principle of intention to treat (i.e. patients as 
randomised in each trial arm and with complete outcome data at follow up).  Where missing 
data were noted within an individual trial, contact with the author was attempted and data 
added if available.  Given the relatively small levels of missing outcome and covariate data 
within trials, we did not undertake data imputation. Where possible, all one-stage and two-
stage analyses used random effects models as the overall dataset is likely to include a high 
degree of clinical heterogeneity across the individual studies (differences in population, 
ExCR intervention and comparator). (29) All analyses were undertaken using Stata 14.2 
StataCorp LP, College Station, Texas, USA.  
 
Main outcomes 
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In accordance with the study research objectives we sought individual patient data for the 
following outcomes from eligible trials:  
1) Mortality: incidence and time-to-event data for all deaths. In addition, we also sought 
to obtain data on the cause of death 
2) Hospital admission: incidence, time-to-event and duration of hospitalisation. We also 
sought to obtain data on the cause of the hospitalisation 
3) Disease specific health-related quality of life, as assessed by the MLHFQ 
questionnaire and other validated HRQoL outcomes: value at baseline (pre-
randomisation) and outcome at 6, 12, 24 and >24 months post-randomisation 
4) Exercise capacity, as assessed by peak oxygen uptake (VO2 peak) and other validated 
exercise capacity measures: outcome at baseline and at 6, 12, 24 and >24 months 
post-randomisation 
 
Patient subgroups  
We also requested individual patient demographic and clinical data, including: age, gender, 
ejection fraction, NYHA class, heart failure aetiology (ischemic vs. non-ischemic), 
race/ethnicity and exercise capacity at baseline). Details of exercise training prescription (i.e. 
session frequency, duration, intensity and overall programme duration) was collected as part 
of the 2014 Cochrane review.  
 
Statistical Analysis Plans 
A detailed Statistical Analysis Plan was produced for each of the three analyses described 
below:  
1) Impact of ExCR on mortality and hospitalisation outcomes  
2) Impact of ExCR on HRQoL and exercise capacity outcomes 
3) Validation of exercise capacity as a surrogate outcome 
 
Descriptive statistics 
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For each analysis, patient-level characteristics were compared for those patients in the ExCR 
and control groups of the included studies. A descriptive of trial-level characteristics by 
group are also reported.  
 
Assessment of study quality and risk of bias 
We checked for potential small study bias by visual assessing funnel plot asymmetry and 
using the Egger test. (30) Study quality and risk of bias was assessed using the TESTEX 
quality assessment tool. (31) Statistical heterogeneity was assessed using the I2 statistic. (29) 
 
Impact of ExCR on mortality and hospitalisation 
Inclusion of trials  
Trials were included in the mortality and hospitalisation analyses if IPD was provided for the 
one or more of the outcomes of interest detailed below.  
 
Outcomes of interest  
The final patient-relevant outcomes of interest in this study were: 
1. Time to event to all-cause mortality 
2. Time to event to HF-related mortality 
3. Time to event to all-cause hospital admission 
4. Time to event to HF-related hospital admission 
 
Due to the inconsistency of reporting in IPD sets, we were only able to consider time to event 
outcomes and not incidence or duration of events. Insufficient data were made available to 
allow analyses on ‘sudden death’ to be carried out.  
 
Each of the outcomes described above were analysed separately. Each trial contributed to 
between one and four analyses.  
 
Primary analysis 
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In the primary analysis, a two-stage IPD meta-analysis approach was taken, with each trial 
first analysed using a Cox regression model and then trial-specific estimates of treatment 
effects (i.e. hazard ratios) or treatment-covariate interactions (i.e. differences in hazard ratios) 
were meta-analysed across studies. A random effects model was used to account for the high 
degree of clinical heterogeneity across the individual studies due to differences in population, 
Ex-CR intervention, and comparator. (29) An overall estimate of the effect of Ex-CR for each 
outcome, both by trial and as a pooled estimate, was presented as a hazard ratio (HR) and 
95% confidence interval (CI). Additionally, the τ2 and I2 statistics were reported alongside the 
associated p-value for the results of the main analyses. (29, 32) The Cochrane handbook advises 
that using specific threshold values for the interpretation of I2 can be misleading. (33) 
 
Secondary analysis 
Secondary analysis used a one-stage IPD meta-analysis Cox regression model, stratified by 
trial. Stratification allowed the baseline hazard to vary between studies, rather than forcing 
the hazard in individual studies to be proportionate to each other. (34) No distributional 
assumptions about this baseline hazard were made. Due to failure of convergence in the one-
stage random effect models, likely due to the low level of heterogeneity between studies, a 
fixed effect approach was used.  
 
The within-trials interaction term used here identifies any patient characteristics which 
influence the effectiveness of Ex-CR on an individual level, necessary for making inferences 
for stratified medicine as recommended by Riley et al. (35) The within-trial interaction effect 
is fixed across trials. Continuous covariates were centred on the mean value within each trial; 
binary covariates were centred on the proportion within each trial.  
 
Sensitivity analyses 
To test the robustness of primary and secondary analyses, we undertook a number of pre-
specified sensitivity analyses: we excluded the largest trial (HF-ACTION(19)); truncated 
outcomes at 1, 2, and 5 years follow up; and included trial level outcome data for studies that 
could not provide IPD. (26)  
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Impact of ExCR on HRQoL and exercise capacity  
Inclusion of trials  
Trials were included in the HRQoL and exercise capacity analyses if IPD was provided for 
the one or more of the outcomes of interest detailed below.  
 
Outcomes of interest  
The final patient-relevant outcomes of interest in this study were: 
1. HRQoL measured using the MLHFQ score 
2. HRQoL measured through any validated scale 
3. Exercise capacity measured using VO2peak (ml/kg/min) 
4. Exercise capacity measured using 6-minute walk test (6MWT) (metres) 
5. Exercise capacity measured using a standardised exercise capacity score calculated 
from any of the four validated exercise capacity measures listed below 
 
HRQoL scales of measurement 
HRQoL measured using one of three validated measures was included in this analysis:  
(i) Minnesota Living with Heart Failure Questionnaire (MLHFQ) (36) 
(ii) Kansas City Cardiomyopathy Questionnaire (KCCQ) (37), and 
(iii) Guyatt scale (38)  
The first HRQoL analysis was carried out for trials providing the MLHFQ data; the second 
analysis used a standardised score calculated from any of the three measures above.  
 
Exercise capacity scales of measurement 
Exercise capacity measured using one of four validated measures was included in this 
analysis:  
(i) VO2peak in ml/kg/min 
(ii) Distance (metres) walked on the 6MWT 
(iii) Distance (metres) walked in an incremental shuttle walk test (ISWT) and  
(iv) Workload on cycle ergometer (watts) 
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Exercise capacity analysis was carried out for: 
(i) Trials providing VO2peak  
(ii) Trials providing 6MWT 
(iii) A standardised exercise capacity score, calculated from any of the validated 
exercise capacity measures listed above.  
One study, HF-ACTION (19), provided data on both VO2peak and 6MWT and was included in 
all analyses, with the VO2peak measure taking precedence for the standardised exercise 
capacity analysis. 
 
Primary analysis 
The primary analyses included one-stage and two-stage IPD meta-analyses carried out at 6 
and 12 months. At each time point, we used the observation closest to and prior to the time 
point. All one-stage IPD models used a hierarchical random effects regression model, 
adjusted for the baseline value of the outcome measure. All two-stage models used random 
treatment effects. We performed a series of models to estimate the overall treatment effect 
and to investigate potential interactions between ExCR and pre-defined patient subgroups 
(i.e., age, gender, left ventricular ejection fraction, heart failure aetiology, NYHA class and 
baseline exercise capacity (23, 27)) Each model investigated one interaction effect only. The I2 
and τ2 statistics were reported alongside the associated p-value for the results of the main 
analyses. (29, 32) 
 
Secondary analysis 
The secondary analyses used a random effects hierarchical model for repeated measures at 
multiple time points. These models utilised HRQoL and exercise capacity outcome data at all 
available time points. Adjustments for baseline values of the outcome measure were made; no 
other covariates were included in the model. This model included a time by treatment 
interaction term.  
 
Sensitivity analyses 
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To test the robustness of the primary analyses, pre-specified sensitivity analyses were carried 
out: 
(i) Primary analysis was repeated after exclusion of the largest trial (HF-ACTION(19)) 
(ii) Addition of aggregate data from studies that did not provide IPD  
 
Surrogate analysis  
Inclusion of trials  
All studies in the ExTraMATCH II meta-analysis were eligible for inclusion in the surrogate 
analyses, dependent on the availability of data on exercise capacity and final patient-relevant 
outcomes, as explained below.  
 
Outcomes of interest  
The final patient-relevant outcomes of interest in this validation study were: 
1. HRQoL measured by MLHFQ score 
2. HRQoL measured through any validated scale 
3. Time to all-cause mortality 
4. Time to all-cause hospital admission 
 
For this study, three approaches to exercise capacity definition were used:  
(i) Direct assessed VO2peak 
(ii) 6MWT 
(iii) Direct and indirect VO2peak (conversion from 6MWT and ISWT. No conversion 
was possible for watts as it is dependent on body weight of individual patients).  
Distances recorded as either 6MWT or ISWT at baseline were converted to VO2peak using 
previously reported methods. (39-43) Details can be found in Appendix 5.  
 
Follow-up time considerations 
The following outcome follow-up times were considered: ≤ 6 months for exercise capacity 
outcomes; ≤12 months for HRQoL outcomes; and all available follow-up time for mortality 
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and hospitalisation. This approach was consistent with the assumption of temporal 
antecedence for a causal relationship between the surrogate endpoint and the final outcomes.  
 
Mediation analysis 
Mediation is known as the phenomenon whereby a cause affects an intermediate variable 
(also called mediator), and the change in the intermediate variable goes on to affect the 
outcome. (44, 45) The effect of the cause on the outcome that operates through the intermediate 
of interest is sometimes referred to as an indirect or mediated effect. Mediation analysis is 
usually referred to the set of techniques by which a researcher assesses the relative magnitude 
of these direct and indirect effects. The product method specification of this approach was 
used to determine whether a change in VO2peak (ΔVO2peak) or a change in 6MWT 
(Δ6MWT) mediate the relationship between treatment assignment (i.e. ExCR vs no ExCR) 
and each of the final outcome of interest. Linear or Cox regression analyses were conducted 
to evaluate the following four hypotheses: 
(i) Treatment assignment (i.e. ExCR vs control) has a significant effect on ΔVO2peak 
or Δ6MWT from baseline to 6 months follow-up;  
(ii) ΔVO2peak or Δ6MWT have a significant effect on ΔMLHFQ or ΔHRQL or on 
the hazards of developing a clinical event;  
(iii) Treatment assignment (i.e. ExCR vs control) has a significant effect on ΔMLHFQ 
or ΔHRQL or on the hazards of developing a clinical event; 
(iv) The effect of treatment assignment (i.e. ExCR vs control) on ΔMLHFQ or 
ΔHRQL or on the hazards of developing a clinical event is attenuated when 
ΔVO2peak or Δ6MWT is added to the model.  
All regression models took into account the clustering within trials to allow for study-level 
differences in treatment effect and unstructured covariance between random intercept and 
random slope. Regression models were adjusted for baseline of either exercise capacity 
values or baseline HRQoL values. No other adjustments were made, because patients were 
randomly assigned to intervention or control arm. For criterion (ii) no adjustment for made 
for potential confounding.  
 
We assumed necessary to reject the null for at least the first of these hypotheses (i.e. the 
treatment assignment is associated with the mediator) to support the validation of ΔVO2peak 
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or Δ6MWT as mediator endpoints and proceed further with the estimation of proportion of 
the proportion explained or proportion mediated.  
 
Meta-analytic approach: R2 and surrogate threshold effect  
Whilst mediation analysis considers pathways by which treatment effects may arise, 
surrogacy principally concerns whether we are able to predict the effect treatment on the final 
endpoint by using the effect of treatment on the surrogate. 
 
Given the issues described with the proportion explained and indirect effects approaches in 
identifying consistent surrogates, the meta-analytic approach may offer the most promise for 
assessing surrogate outcomes and for making policy and treatment decisions. (46, 47) This 
approach requires multiple studies, or at least multiple subgroups (e.g. centres within a trial), 
which we have through the ExTraMATCH II IPD meta-analysis. Because a true and strong 
association between the treatment effect on the final endpoint and the treatment effect on the 
surrogate is considered to be the hallmark of surrogacy, (47) this approach proceeds as follows. 
Let ϕj denote the estimate of the effect of treatment on the final outcome in the jth study, let θj 
denote the estimate of the effect of treatment on the surrogate outcome in the jth study, both 
derived from RCTs. For a good surrogate, a monotonic relationship would exist between ϕj 
and θj and, in a regression of ϕj on θj, there would be limited variability around the regression 
line. If the relationship between ϕj and θj is approximately linear, a reasonable measure of 
surrogacy is the R2trial of the regression of ϕj on θj. Another intuitive measure recommended 
as a surrogacy metric is the surrogate threshold effect (STE), which takes into account the 
variability around the regression line and represents the intercept of the prediction band of the 
regression line with the zero effect line on the final outcome. (46) For each trial we estimated 
study-level treatment effects by conducting linear regression or Cox proportional hazards 
regression models. Adjustment was made for baseline exercise capacity or HRQoL values. 
Then we conducted linear meta-regressions to relate estimated difference in exercise capacity 
to the estimated effect on change in HRQoL log(HR) of all-cause mortality or log(HR) of all-
cause hospitalisation events. The square of the inverse standard error was used as a weight to 
account for uncertainty in the estimated patient-relevant outcomes effect. We calculated 
commonly reported indicators of surrogate validation. (48) The correlation coefficient (ρ) and 
the R2 for the relationship between treatment effect difference on exercise capacity and each 
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of the final outcomes was estimated  individually using weighting by the inverse of the 
variance (for the treatment effect on final outcomes). In order to estimate STE, prediction 
bands where calculated based on approximate prediction intervals. (48, 49) 
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Chapter 4: Characteristics and quality of included studies 
Identification of trials for inclusion in the ExTraMATCH II master dataset 
A total of 23 trials were deemed eligible for the ExTraMATCH II IPD meta-analysis. Data 
from six trials have been analysed previously and were available from the ExTraMATCH 
database.(50-55) Fourteen investigators responded positively and shared their de-identified trial 
data directly. (19, 56-68)  
 
Exclusion of eligible trials from the ExTraMATCH II master dataset 
We were unable to include data from three trials (355 patients); for two trials data were no 
longer available (69, 70) and the investigators of the other trial could not be contacted. (71) After 
obtaining IPD, a further trial (72) was excluded, as it was determined that it included patient 
data that overlapped with another trial. (62) We therefore had a total of 19 trials in the 
ExTraMATCH II study, (19, 50-67) with a total of 3900 patients. A flow diagram to show 
inclusion and exclusion of trials in the ExTraMATCH II study is shown in Figure 1Error! 
Reference source not found.. Further flow diagrams to show inclusion and exclusion of 
trials and participants within individual analyses are given in the appropriate results sections 
below.  
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2014 Cochrane review 
n = 33 trials (n= 46 publications) 
ExTraMATCH II IPD Meta-analysis 
n=23 trials met inclusion criteria 
[n=4,398 patients] 
Excluded trials, n=4 
Datasets destroyed / lost, n=2 
Trial group uncontactable, n=1 
Patients duplicated in another study, n=1 
RCTs included from 
ExTraMATCH I analysis  
n=4 trials 
(n=4 publications) 
Excluded trials, n=14 
Less than 50 patients in trial, n=14 
ExTraMATCH II IPD meta-analysis 
n=19 trials (3,900 patients) provided data 
Figure 1: PRISMA flow diagram summarising selection of studies for the ExTraMATCH II study 
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Characteristics of included patients 
Patient characteristics at baseline were well balanced between ExCR and control patients. 
The majority of patients were male (75%), with a mean age of 61 years (standard deviation 
(SD) 13). The mean baseline left-ventricular ejection fraction was 26.7% (SD 8.1%); no 
included trials recruited patients with preserved ejection fraction heart failure (ejection 
fraction >45%), and most patients were in NYHA functional class II (59%) or III (37%) (see 
Table 1Error! Reference source not found.). 
 
Table 1: Baseline characteristics of patients in the ExTraMATCH II master dataset 
 Characteristic 
ExCR 
(n=1,986) 
Control  
(n=2,003) 
All  
(n=3,989) 
Age (years),  mean (SD) 61.4 (12.8) 61.5 (13.1) 61.4 (13.0) 
Gender  
   Male 
   Female 
 
1455 (73.3) 
531 (26.7) 
 
1511 (75.4) 
492 (24.6) 
 
2966 (74.4) 
1023 (25.7) 
Baseline ejection fraction (%); mean  (SD) 27.2 (8.8) 26.9 (8.7) 26.9 (8.7) 
NYHA status  
   Class I 
   Class II 
   Class III 
   Class IV 
 
25 (1.3) 
1124 (58.6) 
721 (37.6) 
47 (2.5) 
 
29 (1.5) 
1148  (59.5) 
728 (37.7) 
26 (1.4) 
 
54 (1.4) 
2272 (59.0) 
1449 (37.7) 
73 (1.9) 
Aetiology  
   Ischaemic  
   Non-ischemic 
 
1067 (57.3) 
796 (42.7) 
 
1055 (56.1) 
826 (43.9) 
 
2122 (56.7) 
1622 (43.3) 
Ethnicity 
   White 
   Non-white 
 
1130 (70.2) 
480 (29.8) 
 
1163 (71.8) 
458 (28.3) 
 
2293 (71.0) 
938 (29.0) 
VO2 peak (ml/kg/min); mean (SD) 14.9 (4.3) 15.0 (4.6) 15.0 (4.4) 
Data are n (%) unless otherwise indicated; percentages may not sum to 100 because of rounding; NHYA: New 
York Heart Association; SD: standard deviation; VO2 peak: peak oxygen uptake. 
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Characteristics of included trials 
Trials were from Europe and North America and were published between 1990 and 2012. 
Sample size ranged from 50 to 2130 patients. All trials evaluated an aerobic exercise 
intervention, which was most commonly delivered in either an exclusively centre-based 
setting or a centre-based setting in combination with some home exercise sessions. The dose 
of exercise training ranged widely across trials. ExCR was delivered over a period of 12 to 90 
weeks, with between 2 and 7 sessions per week; median session duration was between 15 and 
120 minutes (including warm-up and cool-down). The intensity of exercise ranged between 
50 to 85% peak VO2 (see Table 2Error! Reference source not found.). 
 
Table 2: Characteristics of included trials in the ExTraMATCH II master dataset 
Study characteristics 
Publication year 
   1990 to 1999 
   2000 to 2009 
   2010 to 2012 
   Unpublished 
 
2 (10.5) 
12 (63.2) 
4 (21.0) 
1 (5.3) 
Main study location 
   Europe   
   North America(a) 
 
14 (73.7) 
5 (26.3) 
Single study centre 
   Single 
   Multiple  
   Not reported 
 
13 (68.4) 
5 (26.3) 
1 (5.3) 
Sample size 
   0 to 99 
   100 to 999 
   1000 and over 
 
11 (57.9) 
7 (36.8) 
1 (5.3) 
Duration of follow-up in dataset (months), median (range) 
   Mortality 
 
29 (24) 
Intervention characteristics 
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Intervention type 
   Exercise only programs 
   Comprehensive programs 
   Not reported 
 
13 (68.4) 
5 (26.3) 
1 (5.3) 
Type of exercise 
   Aerobic exercise only 
   Aerobic plus resistance training  
   Not reported 
 
12 (63.2) 
6 (31.6) 
1 (5.3) 
Dose of intervention  
   Duration of intervention (weeks), median (range) 
   Frequency (sessions per week), median (range) 
   Length of exercise session (mins), median (range) 
   Exercise intensity, range 
 
30 (15 to 90)  
2.5 (2 to 6.5) 
24 (4 to 120) 
50-85% VO2peak 
11-15 BORG rating 
Setting 
   Centre-based 
   Home-based 
   Not reported 
 
14 (73.7) 
4 (21.1) 
1 (5.3) 
 
Assessment of study quality and risk of bias in included trials 
The overall quality of included trials was judged to be moderate to good, with a median 
TESTEX score of 11 (range 9 to 14) out of a maximum score of 15 (see Table 3Error! 
Reference source not found.).  
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Table 3: Assessment of quality using TESTEX scale for trials in ExTraMATCH II  
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) 
Belardinelli (1999) 1 0 0 1 0 3 1 1 1 0 0 1 9 
Belardinelli (2012) 1 0 0 1 0 3 1 1 1 0 0 1 9 
DAN-REHAB (2008) 1 1 0 1 1 3 1 2 1 0 0 0 11 
Dracup (2007) 1 0 0 1 0 3 1 2 1 1 1 1 10 
Gary (2010) 1 1 0 1 1 3 1 2 1 0 0 0 11 
Giannuzzi (2003) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Hambrecht (2000) 1 1 0 1 0 3 0 2 1 0 1 1 11 
HF-ACTION (2008) 1 1 1 1 1 3 1 2 1 1 0 1 14 
Jolly (2009) 1 1 1 1 0 2 1 2 1 0 1 1 12 
McKelvie (2002) 1 1 1 1 1 2 1 1 1 0 1 1 12 
Mueller (2007) 1 0 0 1 0 2 1 2 1 0 1 1 10 
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Nilsson (2008) 1 1 0 1 1 2 1 2 1 0 0 1 11 
Passino (2006) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Wielenga (1999) 1 0 0 1 0 2 1 2 1 0 0 1 9 
Willenheimer (2001) 1 0 0 1 1 2 1 2 1 0 0 1 9 
Witham (2005) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Witham (2012) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Yeh (2011) 1 1 0 1 1 3 1 2 1 1 0 0 12 
Zanelli (unpublished)   No score***  
(a) Three points possible;  
(b) If ITT was not specifically mentioned, but it was noted that no participants withdrew and all analysed 1 point was awarded;  
(c) Two points possible;  
Zanelli – not scored as no full publication 
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Chapter 5: Impact of ExCR on mortality and hospitalisation  
One trial which provided IPD was not included in the mortality and hospitalisation analyses 
as no data were provided to allow calculation of survival time or time to hospitalisation. (59) 
This resulted in the inclusion of 18 trials, (19, 50, 51, 53-58, 60-67, 73) comprising 3,912 patients 
(1,948 ExCR, 1,964 control) with a median follow up of 19 months for mortality outcomes 
and 11 months for hospitalisation outcomes. Figure 2 summarises the study selection process 
for the mortality and hospitalisation analyses.  
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2014 Cochrane review 
n = 33 trials (n= 46 publications) 
ExTraMATCH II IPD Meta-analysis 
n=23 trials met inclusion criteria 
[n=4,398 patients] 
Excluded trials, n=5 
Datasets destroyed / lost, n=2 
Trial group uncontactable, n=1 
Patients overlapped in another 
trial, n=1 
No IPD available on events, n=1 
RCTs included from 
ExTraMATCH I analysis  
n=4 trials 
(n=4 publications) 
Excluded trials, n=14 
Patient n < 50, n=14 
ExTraMATCH II IPD Meta-analysis 
n=18 trials provided data 
[n=3,912 patients] 
All-cause mortality 
IPD analysis 
n= 17 trials provided data 
[n= 3,782 patients] 
HF-related mortality 
IPD analysis 
n= 9 trials provided data 
[n= 915 patients] 
All-cause admissions 
IPD analysis 
n= 11 trials provided data 
[n= 3,190 patients] 
HF-related admissions 
IPD analysis 
n= 13 trials provided data 
[n= 3,494 patients] 
Figure 2: PRISMA flow diagram summarising selection of studies for mortality and hospitalisation analyses 
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Characteristics of included patients and trials 
Patient baseline characteristics were well balanced between ExCR and control patients (see 
Table 4). The majority of patients were male (75%), with a mean age of 61 years (standard 
deviation (SD) 13. The mean baseline left-ventricular ejection fraction was 27% (SD 8.1%), 
no included studies recruited patients with preserved ejection fraction heart failure (ejection 
fraction >45%), and most patients were in NYHA functional class II (59%) or III (37%).  
Studies were published between 1999 and 2012 across a number of countries (see Table 2). 
Sample size ranged from 50 to 2,130 patients. All trials evaluated an aerobic exercise 
intervention; six also included resistance training. (52, 57, 58, 61, 64, 65) Exercise training was most 
commonly delivered in either an exclusively centre-based setting or a centre-based setting in 
combination with some home exercise sessions (see Table 5). Three trials were conducted in 
an exclusively home-based setting. (52, 54, 58) The dose of exercise training ranged widely 
across studies with an average session duration of 15 to 120 minutes (including warm-up and 
cool-down), 2 to 7 sessions/week, exercise intensity equivalent of 50 to 85% VO2peak, and 
delivered over a duration of 12 to 90 weeks.  
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Table 4: Baseline characteristics of patients in the mortality and hospitalisation analyses 
 Characteristic 
ExCR 
(n=1,948) 
Control  
(n=1,964) 
All  
(n=3,912) 
Age (years),  mean (SD) 61.3 (12.7) 61.4 (13.2) 61.3 (13.0) 
Gender  
   Male 
   Female 
 
1442 (74) 
506 (26) 
 
1489 (76) 
475 (24) 
 
2,931 (75) 
981 (25) 
Baseline ejection fraction (%); mean  (SD) 26.8 (8.2) 26.7 (8.1) 26.7 (8.1) 
NYHA status  
   Class I 
   Class II 
   Class III 
   Class IV 
 
25 (1) 
1107 (59) 
700 (37) 
47 (3) 
 
28 (1) 
1130 (60) 
708 (37) 
26 (1) 
 
53 (1) 
2237 (59) 
1408 (37) 
73 (2) 
Aetiology  
   Ischaemic  
   Non-ischemic 
 
1094 (57) 
809 (43) 
 
1080 (56) 
838 (44) 
 
2174 (57) 
1647 (43) 
Ethnicity 
   White 
   Non-white 
 
1100 (70) 
472 (30) 
 
1140 (72) 
445 (28) 
 
2240 (71) 
917 (29) 
VO2 peak (ml/kg/min);  
mean (SD) 
14.9 (4.4) 15.0 (4.6) 14.9 (4.5) 
Data are n (%) unless otherwise indicated; percentages may not sum to 100 because of rounding; NHYA: New 
York Heart Association; SD: standard deviation; VO2 peak: peak oxygen uptake. 
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Table 5: Characteristics of included trials in the mortality and hospitalisation analyses 
Study characteristics 
Publication year 
   1990 to 1999 
   2000 to 2009 
   2010 to 2012 
   Unpublished 
 
2 (11) 
12 (67) 
3 (17) 
1 (6) 
Main study location 
   Europe   
   North America(a) 
 
14 (78) 
4 (22) 
Single study centre 
   Single 
   Multiple  
   Not reported 
 
12 (67) 
5 (28) 
1 (6) 
Sample size 
   0 to 99 
   100 to 999 
   1000 and over 
 
10 (56) 
7 (39) 
1 (6) 
Duration of follow-up in dataset (months), median (range) 
   Mortality 
   Hospitalisation 
 
18.6 (11.8 to 419) 
11.2 (2.6 to 98) 
Intervention characteristics 
Intervention type 
   Exercise only programs 
   Comprehensive programs 
   Not reported 
 
5 (28) 
12 (67) 
1 (6) 
Type of exercise 
   Aerobic exercise only 
   Aerobic plus resistance training  
 
12 (67) 
6 (33) 
Dose of intervention  
   Duration of intervention (weeks), median (range) 
 
30 (12 to 90) 
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   Frequency (sessions per week), median (range) 
   Length of exercise session (mins), median (range) 
   Exercise intensity, range 
 
 
2.8 (2 to 7) 
24 (15 to 120) 
40-80% maximum heart rate 
50-85% peak VO2 
12-18 Borg rating  
Setting 
   Centre-based only 
   Home-based only 
   Centre- and home-based 
   Not reported 
 
6 (33) 
3 (17) 
8 (44) 
1 (6) 
Data are n (%) unless otherwise indicated; percentages may not sum to 100 because of rounding;  
(a) HF-ACTION (O’Connor) study was categorised as North America but was also delivered in to a small 
number of patients in France 
 
Assessment of study quality and risk of bias  
There was no evidence of significant small study bias for the four outcomes (see Figure 
3Error! Reference source not found.).  The overall quality of included trials was judged to 
be moderate to good, with a median TESTEX (31) score of 11 (range 9 to 14) out of a 
maximum score of 15 (Table 6Error! Reference source not found.).  The criteria of 
allocation concealment and physical activity monitoring in the control groups were met in 
only three studies (19, 58, 66); the other TESTEX criteria were met in 50% or more of trials.  
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a. All-cause mortality       
Egger test -0.26, p=0.458                                                
 
 
b. HF-specific mortality  
Egger test -1.60, p=0.147 
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c.  All-cause hospitalisation  
Egger test 0.16, p=0.739                                                             
 
 
d. HF-specific hospitalisation 
Egger test 0.32, p=0.610 
 
Figure 3: Funnel plots for mortality and hospitalisation analyses 
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Table 6: Assessment of quality using TESTEX scale of included studies in mortality and hospitalisation analysis 
Study (publication 
year) 
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) 
Belardinelli (1999) 1 0 0 1 0 3 1 1 1 0 0 1 9 
Belardinelli (2012) 1 0 0 1 0 3 1 1 1 0 0 1 9 
DANREHAB (2008) 1 1 1 1 1 3 1 2 1 0 0 0 12 
Dracup (2007) 1 0 0 1 0 3 1 2 1 1 1 1 10 
Giannuzzi (2003) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Hambrecht (2000) 1 1 0 1 0 3 0 2 1 0 1 1 11 
HF-ACTION (2008) 1 1 1 1 1 3 1 2 1 1 0 1 14 
Jolly (2009) 1 1 1 1 0 2 1 2 1 0 1 1 12 
McKelvie (2002) 1 1 1 1 1 2 1 1 1 0 1 1 12 
Mueller (2007) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Nilsson (2008) 1 1 0 1 1 2 1 2 1 0 0 1 11 
Passino (2006) 1 0 0 1 0 2 1 2 1 0 1 1 10 
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Wielenga (1999) 1 0 0 1 0 2 1 2 1 0 0 1 9 
Willenheimer (2001) 1 0 0 1 1 2 1 2 1 0 0 1 9 
Witham (2005) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Witham (2012) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Yeh (2011) 1 1 0 1 1 3 1 2 1 1 0 0 12 
Zanelli (unpublished) Not scored 
(a) Three points possible;  
(b) If ITT was not specifically mentioned, but it was noted that no participants withdrew and all analysed 1 point was awarded;  
(c) Two points possible;  
Zanelli – not scored as no full publication 
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Findings 
Primary analysis 
Compared to control, all time to event mean treatment effects from random effects 2-stage 
IPD meta-analysis were in favour of ExCR but with wide confidence intervals and not 
statistically significant , i.e. all-cause mortality: HR: 0.83 (95% CI: 0.67 to 1.04, p=0.107, 17 
studies, 3,782 patients, τ2=0.04, I2 =26%); HF-specific mortality (HR: 0.84, 95% CI: 0.48 to 
1.46, p=0.527, 9 studies, 915 patients, τ2=0.00, I2 =0%); all-cause hospitalisation (HR: 0.90, 
95% CI: 0.76 to 1.06, p=0.210, 11 studies, 3,190 patients, τ2=0.01, I2 =12.4%,), and HF-
specific hospitalisation (HR: 0.98, 95% CI: 0.72 to 1.35, p=0.902, 13 studies, 3,494 patients, 
τ2=0.10, I2 =45%) (see Figure 4 Error! Reference source not found.and Tables 7-10) 
 
Interaction analyses for the two-stage model revealed no consistent interaction between the 
effect of ExCR and any of the predefined subgroups (age, gender, ejection fraction, NYHA 
class, HF aetiology, ethnicity or baseline exercise capacity) for all-cause mortality, HF-
related mortality, all-cause hospitalisation, or HF-related hospitalisation (see Tables 7-10). In 
order to make further comparisons of mortality and hospitalisation rates within each 
subgroup, the HR and associated 95% CI from individual subgroup one-stage IPD meta-
analyses are shown in Figure 5. The p-value from the interaction test in the two-stage IPD 
meta-analyses are presented alongside these estimates. 
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a. All-cause mortality                                                                   b. HF-specific mortality  
  
c. All-cause hospitalisation                                                  d. HF-specific hospitalisation 
Figure 4: Effect of ExCR on mortality and hospitalisation across patient subgroups: 
Two –stage IPD meta-analysis 
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Table 7: All-cause mortality - overall treatment effect and subgroup (interaction) effects 
 
Primary 
analysis 
Secondary 
analysis 
Sensitivity analyses 
  Two-stage 
model,  
random effects 
HR (95% CI) 
p-value 
One-stage Cox 
model, 
stratified by 
study with 
fixed  
treatment 
effect 
HR (95% CI) 
p-value 
Two-stage 
model,  
random effects 
excluding HF-
Action 
HR (95% CI) 
p-value 
 
One-stage Cox 
model, 
stratified by 
study with 
fixed  
effect 
excluding  
HF-Action 
HR (95% CI) 
p-value 
Two-stage 
model, 
random effects 
1 year 
truncation 
HR (95% CI) 
p-value 
Two-stage 
model, 
random effects 
2 year 
truncation 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
5 year 
truncation 
HR (95% CI) 
p-value 
Overall effect 0.83 (0.67, 
1.04) 
p=0.107 
0.85 (0.73, 
0.99) 
p=0.034 
0.81 (0.61, 
1.06) 
p=0.129 
0.79 (0.64, 
0.97) 
p=0.027 
0.87 (0.58, 
1.31) 
p=0.507 
0.86 (0.67, 
1.10) 
p=0.217 
0.84 (0.66, 
1.06) p=0.140 
Interaction terms 
Age 
(years) 
0.99 (0.98, 
1.00) 
p=0.165 
0.99 (0.98, 
1.01) 
p=0.254 
0.98 (0.96, 
1.01) 
p=0.144 
0.99 (0.96, 
1.01) 
p=0.228 
0.98 (0.95, 
1.00) 
p=0.077 
0.98 (0.96, 
1.00) 
p=0.034 
0.99 (0.97, 
1.00) 
p=0.097 
Gender 
(male vs 
female) 
1.10 (0.73, 
1.66) 
p=0.660 
1.06 (0.70, 
1.60) 
p=0.783 
0.71 (0.35, 
1.43) 
p=0.341 
0.70 (0.36, 
1.36) 
p=0.300 
0.76 (0.34, 
1.68) 
p=0.490 
0.96 (0.55, 
1.67) 
p=0.872 
1.17 (0.75, 
1.82) 
p=0.481 
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Ejection 
fraction (%) 
0.99 (0.97, 
1.01) 
p=0.250 
0.99 (0.97, 
1.01) 
p=0.332 
0.98 (0.95, 
1.01) 
p=0.124 
0.98 (0.96, 
1.01) 
p=0.201 
1.04 (1.00, 
1.08) 
p=0.055 
0.99 (0.97, 
1.02) 
p=0.688 
0.99 (0.97, 
1.01) 
p=0.506 
NYHA class  
(NYHA I/II vs 
NYHA III/IV) 
0.80 (0.58, 
1.11) 
p=0.182 
0.79 (0.57, 
1.08) 
p=0.134 
0.82 (0.49, 
1.38) 
p=0.459 
0.75 (0.46, 
1.22) 
p=0.244 
0.50 (0.23, 
1.07) 
p=0.073 
0.84 (0.54, 
1.30) p=0.431 
0.83 (0.59. 
1.18) 
p=0.297 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.73 (0.38, 
1.39)  
p=0.335 
1.19 (0.86, 
1.64)  
p=0.297 
0.69 (0.36, 
1.31)  
p=0.255 
0.87 (0.54, 
1.41) 
p=0.575 
0.69 (0.19, 
2.54) 
p=0.574 
0.79 (0.38, 
1.67)  
p=0.542 
0.70 (0.33, 
1.47)  
p=0.345 
Ethnic group  
(white vs non-
white) 
1.12 (0.74, 
1.69) 
p=0.593 
1.11 (0.74, 
1.68) 
p=0.604 
(a) 1.05 (0.25, 
4.31) 
p=0.949 
0.72 (0.34, 
1.53) 
p=0.396 
0.83 (0.50, 
1.38) 
p=0.468 
1.12 (0.74, 
1.69) 
p=0.593 
Exercise capacity 
Baseline peak 
VO2 directly 
measured 
1.00 (0.95, 
1.05) 
p=0.937 
0.99 (0.95, 
1.04) 
p=0.783 
0.98 (0.90, 
1.08) 
p=0.712 
0.99 (0.91, 
1.07) 
p=0.777 
0.97 (0.88, 
1.06) 
p=0.456 
0.99 (0.93, 
1.05) 
p=0.780 
0.98 (0.91, 
1.06) 
p=0.630 
Baseline peak 
VO2, directly 
measured and 
predicted 
1.00 (0.95, 
1.06) 
p=0.903 
1.00 (0.96, 
1.04) 
p=0.954 
1.00 (0.91, 
1.08) 
p=0.923 
1.00 (0.93, 
1.07) 
p=0.984 
0.99 (0.90, 
1.08) 
p=0.734 
1.00 (0.94, 
1.06) 
p=0.961 
1.00 (0.93, 
1.07) 
p=0.924 
Standardised 
scores using 
baseline peak 
VO2, 6MWT, 
1.03 (0.83, 
1.27) 
p=0.802 
1.02 (0.85, 
1.22) 
p=0.851 
0.99 (0.71, 
1.39) 
p=0.955 
1.01 (0.75, 
1.35) 
p=0.967 
0.97 (0.66, 
1.41) 
p=0.858 
1.00 (0.78, 
1.30) 
p=0.972 
1.01 (0.76, 
1.35) 
p=0.938 
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ISWT units, 
and watts 
(a) Study estimate not available as too few studies provide data; peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 
6MWT: 6-minute walk test. 
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Table 8: HF-specific mortality - overall treatment effect and subgroup (interaction) effects^ 
 Primary 
analysis 
Secondary analysis Sensitivity analyses 
  Two-stage 
model,  
random effects 
HR (95% CI) 
p-value 
One-stage Cox 
model, 
stratified by study 
with fixed  
treatment effect 
HR (95% CI) 
p-value 
Two-stage model,  
random effects 
1 year truncation 
HR (95% CI) 
p-value  
Two-stage model,  
random effects 
2 year truncation 
HR (95% CI) 
p-value  
Two-stage model, 
random effects 
5 year truncation 
HR (95% CI) 
p-value 
Overall effect 0.84 (0.48, 1.46) 
p=0.527 
0.75 (0.44, 1.28) 
p=0.294 
(a) 1.30 (0.59, 2.87) 
p=0.515 
0.84 (0.49, 1.53) 
p=0.575 
Interaction terms 
Age (years) 0.96 (0.91, 1.02) 
p=0.206 
0.96 (0.92, 1.01) 
p=0.162 
(a) 0.91 (0.84, 0.98) 
p=0.017 
0.95 (0.90, 1.00) 
p=0.066 
Gender (male vs 
female) 
0.53 (0.08, 3.73) 
p=0.524 
0.61 (0.11, 3.49) 
p=0.583 
(a) (b) (b) 
Ejection fraction (%) 0.95 (0.89, 1.02) 
p=0.159 
0.96 (0.90, 1.02) 
p=0.179 
(a) 1.01 (0.82, 1.24) 
p=0.912 
0.96 (0.89, 1.04) 
p=0.309 
NYHA class (NYHA 
I/II vs NYHA III/IV) 
0.54 (0.07, 4.28) 
p=0.562 
0.78 (0.23, 26.65) 
p=0.691 
(a) (b) 0.54 (0.07, 4.28) 
p=0.562 
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HF aetiology 
(ischaemic vs non-
ischaemic) 
Data only 
available for one 
study 
3.30 (1.02, 10.7) 
p=0.047 
(a) (b) (b) 
Ethnic group (white 
vs non-white) 
(b) (b) (a) (b) (b) 
Exercise capacity: 
Baseline peak VO2, 
directly measured 
0.90 (0.76, 1.07) 
p=0.232 
0.93 (0.78, 1.09) 
p=0.362 
(a) 0.98 (0.73, 1.31) 
p=0.893 
0.86 (0.69, 1.06) 
p=0.146 
Baseline peak VO2, 
directly measured and 
predicted 
0.91 (0.77, 1.07) 
p=0.263 
0.94 (0.80, 1.10) 
p=0.423 
(a) 0.98 (0.76, 1.26) 
p=0.854 
0.88 (0.72, 1.06) 
p=0.184 
Standardised scores 
using baseline peak 
VO2, 6MWT, ISWT 
units and watts score 
0.69 (0.35, 1.35) 
p=0.276 
0.82 (0.43, 1.56) 
p=0.545 
(a) 0.86 (0.31, 2.37) 
p=0.773 
0.61 (0.28, 1.32) 
p=0.210 
(a) HF-Action did not provide HF-mortality so sensitivity analysis of omission not undertaken;  
(b) Study estimate not available as too few studies provide data 
Peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test 
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Table 9: All-cause hospitalisation - overall treatment effect and subgroup (interaction) effects 
 
Primary 
analysis 
Secondary 
analysis 
Sensitivity analyses 
 
Two-stage 
model,  
random effects 
HR (95% CI) 
p-value 
One-stage Cox 
model, 
stratified by 
study with 
fixed  
treatment 
effect 
HR (95% CI) 
p-value 
Two-stage 
model,  
random effects 
excluding  
HF-Action 
HR (95% CI) 
p-value 
 
One-stage Cox 
model, 
stratified by 
study with 
fixed  
treatment 
effect 
excluding  
HF-Action 
HR (95% CI) 
p-value 
Two-stage 
model,  
random effects 
1 year 
truncation 
HR (95% CI) 
p-value  
Two-stage 
model,  
random effects 
2 year 
truncation 
HR (95% CI) 
p-value  
Two-stage 
model,  
random effects 
5 year 
truncation 
HR (95% CI) 
p-value  
Overall effect 0.90 (0.76, 
1.06) 
p=0.210 
0.91 (0.83, 
1.01) 
p=0.072 
0.86 (0.64, 
1.14) 
p=0.293 
0.85 (0.68, 
1.09) 
p=0.210 
0.94 (0.75, 
1.18) 
p=0.583 
0.91 (0.74, 
1.11) 
p=0.330 
0.90 (0.76, 
1.06) 
p=0.210 
Interaction terms 
Age (years) 1.00 (0.99, 
1.01) 
p=0.794 
1.00 (0.99, 
1.01) 
p=0.854 
1.00 (0.98, 
1.03) 
p=0.808 
1.00 (0.98, 
1.02) 
p=-0.969 
1.00 (0.99, 
1.01) 
p=0.636 
1.00 (0.99, 
1.01) 
p=0.798 
1.00 (0.99, 
1.01)  
p=0.794 
Gender (male 
vs female) 
1.09 (0.87, 
1.36) 
p=0.454 
1.09 (0.88, 
1.36) 
p=0.424 
0.66 (0.38, 
1.14) 
p=0.136 
0.68 (0.39, 
1.16) 
p=0.158 
1.05 (0.80, 
1.37) 
p=0.745 
1.15 (0.91, 
1.46) 
p=0.239 
1.09 (0.87, 
1.35) 
p=0.454 
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Ejection 
fraction (%) 
1.00 (0.98, 
1.01) 
p=0.629 
1.00 (0.98, 
1.01) 
p=0.646 
1.00 (0.96, 
1.04) 
p=0.857 
1.00 (0.96, 
1.05) 
p=0.831 
1.00 (0.98, 
1.01) 
p=0.632 
0.99 (0.98, 
1.01) 
p=0.343 
1.00 (0.98, 
1.01) 
p=0.629 
NYHA class 
(NYHA I/II vs 
NYHA III/IV) 
0.91 (0.74, 
1.12) 
p=0.370 
0.90 (0.73, 
1.10) 
p=0.308 
0.89 (0.43, 
1.87) 
p=0.763 
0.79 (0.39, 
1.60) 
p=0.508 
0.81 (0.63, 
1.05) 
p=0.110 
0.87 (0.70, 
1.09) 
p=0.235 
0.91 (0.74, 
1.12) 
p=0.355 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.96 (0.71, 
1.31) 
p=0.810 
1.00 (0.82, 
1.22) 
p=0.988 
0.73 (0.39, 
1.39) 
p=0.340 
0.73 (0.40, 
1.31) 
p=0.284 
1.08 (0.84, 
1.38) 
p=0.562 
1.04 (0.84, 
1.29) 
p=0.723 
1.01 (0.83, 
1.24) 
p=0.910 
Ethnic group 
(white vs non-
white) 
1.02 (0.83, 
1.26) 
p=0.860 
1.02 (0.83, 
1.26) 
p=0.852 
1.02 (0.47, 
2.21) 
p=0.959 
1.06 (0.49, 
2.32) 
p=0.879 
1.14 (0.88, 
1.48) 
p=0.322 
1.06 (0.85, 
1.33) 
p=0.607 
1.02 (0.83, 
1.26) 
p=0.860 
Exercise capacity: 
Baseline peak 
VO2, directly 
measured 
1.01 (0.99, 
1.04) 
p=0.259 
1.02 (0.99, 
1.04) 
p=0.234 
1.05 (0.95, 
1.16) 
p=0.352 
1.06 (0.96, 
1.17) 
p=0.262 
1.03 (0.99, 
1.06) 
p=0.124 
1.02 (0.99, 
1.04) 
p=0.243 
1.01 (0.99, 
1.04) 
p=0.259 
Baseline peak 
VO2, directly 
measured and 
predicted 
1.02 (0.99, 
1.04) 
p=0.153 
1.02 (0.99, 
1.04) 
p=0.134 
1.07 (0.98, 
1.17) 
p=0.125 
1.08 (0.99, 
1.17) 
p=0.078 
1.03 (1.00, 
1.06) 
p=0.057 
1.02 (0.99, 
1.05) 
p=0.129 
1.02 (0.99, 
1.04) 
p=0.153 
Standardised 
scores using 
baseline peak 
VO2, 6MWT, 
1.09 (0.98, 
1.22) 
p=0.095 
1.10 (0.99, 
1.22) 
p=0.088 
1.30 (0.93, 
1.83) 
p=0.120 
1.32 (0.95, 
1.82) 
p=0.097 
1.16 (1.02, 
1.33) 
p=0.027 
1.11 (0.99, 
1.24) 
p=0.077 
1.09 (0.98, 
1.22) 
p=0.095 
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ISWT units and 
watts 
Peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test. 
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Table 10: HF-specific hospitalisation - overall treatment effect and subgroup (interactions) effects in studies included in IPD meta-
analysis 
 
Primary analysis Secondary 
analysis 
Sensitivity analyses 
 
Two-stage 
model,  
random effects 
HR (95% CI) 
p-value 
One-stage Cox 
model, 
stratified by 
study with 
fixed  
treatment 
effect 
HR (95% CI) 
p-value 
Two-stage model,  
random effects 
excluding  
HF-Action 
HR (95% CI) 
p-value 
 
One-stage 
Cox model, 
stratified by 
study with 
fixed  
treatment 
effect 
excluding  
HF-Action 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
1 year 
truncation 
HR (95% CI) 
p-value  
 
Two-stage 
model,  
random 
effects 
2 year 
truncation 
HR (95% 
CI) 
p-value  
Two-stage 
model,  
random 
effects 
5 year 
truncatio
n 
HR (95% 
CI) 
p-value  
Overall effect 0.98 (0.72, 1.35) 
p=0.902 
0.94 (0.81, 1.08) 
p=0.368 
1.00 (0.65, 1.54) 
p=0.999 
1.03 (0.79, 
1.35) 
p=0.829 
1.08 (0.88, 
1.33) 
p=0.470 
1.06 (0.83, 
1.34) 
p=0.658 
0.97 (0.70, 
1.34) 
p=0.855 
Interaction terms 
Age (years) 1.00 (0.99, 1.02) 
p=0.603 
1.00 (0.99, 1.02) 
p=0.632 
1.00 (0.98, 1.03) 
p=0.958 
1.00 (0.97, 
1.02) 
p=0.906 
1.00 (0.99, 
1.02) 
p=0.640 
1.00 (0.99, 
1.02) 
p=0.611 
1.00 
(0.99, 
1.02) 
p=0.580 
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Gender (male vs 
female) 
1.03 (0.73, 1.46) 
p=0.865 
0.99 (0.71, 1.39) 
p=0.949 
0.70 (0.32, 1.53) 
p=0.372 
0.65 (0.33, 
1.29) 
p=0.215 
0.76 (0.46, 
1.24) 
p=0.274 
1.06 (0.68, 
1.66) 
p=0.803 
0.93 
(0.49, 
1.75) 
p=0.815 
Ejection fraction 
(%) 
0.51 (0.14, 1.79) 
p=0.291 
0.99 (0.97, 1.01) 
p=0.325 
0.99 (0.96, 1.03) 
p=0.540 
0.99 (0.97, 
1.01) 
p=0.350 
0.99 (0.97, 
1.02) 
p=0.569 
0.99 (0.97, 
1.01) 
p=0.350 
0.99 
(0.97, 
1.02) 
p=0.569 
NYHA class 
(NYHA I/II vs 
NYHA III/IV) 
1.55 (0.79, 3.02) 
p=0.200 
1.14 (0.84, 1.54) 
p=0.399 
2.05 (0.86, 4.92) 
p=0.107 
1.74 (0.92, 
3.29) 
p=0.089 
0.81 (0.51, 
1.29) 
p=0.375 
1.17 (0.68, 
2.03) 
p=0.573 
1.21 
(0.72, 
2.04) 
p=0.475 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
1.20 (0.64, 2.25) 
p=0.577 
1.28 (0.94, 1.74) 
p=0.111 
0.95 (0.31, 2.95) 
p=0.928 
1.10 (0.57, 
2.16) 
p=0.771 
1.47 (0.94, 
2.29) 
p=0.128 
1.28 (0.90, 
1.84) 
p=0.172 
1.29 
(0.79, 
2.12) 
p=0.309 
Ethnic group 
(white vs non-
white) 
1.18 (0.85, 1.65) 
p=0.318 
1.19 (0.86, 1.66) 
p=0.291 
(a) 1.79 (0.60, 
5.37) 
p=0.301 
1.25 (0.79, 
1.98) 
p=0.334 
1.20 (0.83, 
1.74) 
p=0.327 
1.18 
(0.85, 
1.65) 
p=0.318 
Exercise capacity: 
Baseline 
peakVO2, directly 
measured 
0.97 (0.88, 1.07) 
p=0.538 
0.97 (0.93, 1.01) 
p=0.149 
0.94 (0.80, 1.11) 
p=0.467 
0.98 (0.90, 
1.07) 
p=0.658 
0.99 (0.90, 
1.10) 
p=0.882 
0.99 (0.93, 
1.06) 
p=0.769 
0.98 
(0.89, 
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1.08) 
p=0.685 
Baseline peak 
VO2, directly 
measured and 
predicted 
0.97 (0.89, 1.07) 
p=0.539 
0.97 (0.93, 1.01) 
p=0.116 
0.95 (0.82, 1.10) 
p=0.483 
0.97 (0.89, 
1.05) 
p=0.424 
0.98 (0.92, 
1.05) 
p=0.610 
0.99 (0.94, 
1.03) 
p=0.535 
0.98 
(0.90, 
1.07) 
p=0.670 
Standardised 
scores using 
baseline peak 
VO2, 6MWT, 
ISWT units and 
watts 
0.88 (0.62, 1.26) 
p=0.483 
0.86 (0.72, 1.03) 
p=0.093 
0.83 (0.46, 1.49) 
p=0.527 
0.81 (0.56, 
1.16) 
p=0.246 
0.92 (0.69, 
1.23) 
p=0.576 
0.93 (0.75, 
1.16) 
p=0.517 
0.91 
(0.69, 
1.20) 
p=0.505 
(a) Study estimate not available as too few studies provide data;  
Peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test. 
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a. All-cause mortality                                             
 
b. HF-specific mortality 
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c. All-cause hospitalisation                                 
 
d. HF-specific hospitalisation 
*although stratified meta-analyses are shown, the interaction P-values are calculated based on 
continuous distribution of age, ejection fraction, and baseline exercise capacity  
 
Figure 5: Effect of ExCR on mortality and hospitalisation across patient subgroups: 
Individual subgroup one-stage IPD meta-analyses
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Secondary analysis 
These primary analysis results were broadly consistent across secondary analyses.  
  
Sensitivity analyses 
In sensitivity analyses, four weak interaction effects (p<0.05) were seen: (1) age vs. all-cause 
mortality (p=0.034) in two-stage model 2 year truncation model, i.e. larger reduction in all-
cause mortality with ExCR in older patients; (2) age vs. HF-mortality (p=0.017) in two-stage 
2-year truncation model, i.e. larger reduction in HF-mortality with ExCR in older patients; (3) 
ischemic status vs. HF-mortality (p=0.047) in one-stage model, i.e. larger reduction in HF-
mortality with ExCR in ischemic patients; and  (4) standardised baseline exercise capacity vs. 
all-cause hospitalisation (p=0.027) in two-stage 1-year truncation model – larger reduction in 
all-cause hospitalisation with ExCR in patients with lower than average baseline exercise 
capacity (see Tables 7-10). Inferences did not change following the addition of trial level data 
from trials that met our study inclusion criteria but were not able to contribute IPD (data not 
shown here, available from authors).  
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Chapter 6: Impact of ExCR on HRQoL and exercise capacity  
Six trials which provided IPD but had no data on HRQoL or exercise capacity were excluded 
from analyses in this section. (50, 52, 54, 55, 57, 73) In addition to comparing usual care to an 
intervention arm of usual care plus ExCR, Gary (59) also compared the effects of cognitive 
behaviour therapy to cognitive behaviour therapy plus ExCR. For the purpose of analysis 
from this point forward, this will be described as one trial providing two comparisons. For 
analysis the dataset was split into two and analysed as if the data were provided by two 
separate trials. For the HRQoL analysis, 9 trials (10 comparisons) provided data for 3,000 
patients (1,496 ExCR, 1,504 control) with a median follow-up of 33 weeks. (19, 58, 59, 61, 63-67) 
For the exercise capacity analysis, 13 trials (14 comparisons) provided 3,332 patients (1,662 
ExCR, 1,670 control) with a median follow-up of 26 weeks. (19, 51, 56, 58-67). Error! Reference 
source not found. Figure 6 summarises the study selection process.  
 
Characteristics of included patients and trials 
Patient baseline characteristics were well balanced between ExCR and control patients (see 
Table 11). The majority of patients were male (73%) with a mean age of 61 years. The mean 
baseline left-ventricular ejection fraction was 27%, and less than 5 percent of included 
patients had a preserved ejection fraction heart failure (defined as ejection fraction > 45%), 
and most patients were in NYHA functional class II (62%) or III (36%).  Studies were 
published between 2000 and 2012 across a number of countries (see Table 12). Sample size 
ranged from 50 to 2,130 patients. All trials evaluated an aerobic exercise intervention; four 
also included resistance training. (58, 61, 64, 65) Exercise training was most commonly delivered 
in an exclusively centre-based setting. Four trials were conducted in an exclusively home-
based setting. (58, 59, 61, 67) The dose of exercise training ranged across studies with an average 
session duration of 15 to 60 minutes (including warm-up and cool-down), 2 to 7 
sessions/week, exercise intensity equivalent of 40 to 70% peak VO2, and delivered over a 
duration of 4 to 120 weeks.  
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Figure 6: PRISMA flow diagram summarising selection of studies for HRQoL and exercise capacity analyses 
2014 Cochrane review 
n = 33 trials (n= 46 publications) 
ExTraMATCH II IPD Meta-analysis 
n=23 trials met inclusion criteria 
[n=4,398 patients] 
RCTs included from 
ExTraMATCH I analysis  
n=4 trials 
(n=4 publications) 
Excluded trials, n=14 
Less than 50 patients in trial, n=14 
ExTraMATCH II IPD meta-analysis 
n=19 trials (3,990 patients) provided data 
n=13 trials (14 comparisons, 3,332 patients) provided either HRQoL or exercise capacity data 
Exercise capacity IPD meta-analysis 
Peak VO2, directly reported 
n= 7 trials provided data (2,685 patients) provided data 
6MWT, directly reported 
n= 8 trials provided data (2,717 patients) provided data 
All exercise capacity outcomes 
n= 13 trials, 14 comparisons (3,332 patients) provided data 
 
Excluded trials, n=4 
Datasets destroyed / lost, n=2 
Trial group uncontactable, n=1 
Patients duplicated in another study, n=1 
HRQoL IPD meta-analysis 
MLHFQ 
n= 8 trials provided data (759 patients) provided data 
All HRQoL outcomes 
n= 9 trials, 10 comparisons (2,970 patients) provided data 
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Table 11: Baseline characteristics of patients in the HRQoL and exercise capacity 
analyses 
 Characteristic 
ExCR 
(n=1,662) 
Control 
(n=1,670) 
All  
(n=3,332) 
Age (years),  mean (SD) 60.9 (13.2) 61.2 (13.5) 61.1 (13.4) 
Gender  
   Male 
   Female 
 
1,187 (71.4) 
475 (28.6) 
 
1,237 (74.1) 
433 (25.9) 
 
2,424 (72.8) 
908 (27.3) 
Baseline ejection fraction (%); mean  (SD) 27.0 (8.8) 26.9 (8.7) 26.9 (8.8) 
Baseline ejection fraction: 
   HFrEF (< 45%) 
   HFpEF (≥ 45%) 
 
1,721 (96.8) 
57 (3.2) 
 
1,744 (97.5) 
45 (2.5) 
 
3,465 (97.1) 
102 (2.9) 
NYHA status  
   Class I 
   Class II 
   Class III 
   Class IV 
 
20 (1.2) 
1,002 (61) 
597 (36) 
19 (1.2) 
 
25 (1.5) 
1,032 (63) 
569 (35) 
18 (1.1) 
 
45 (1.4) 
2,034 (62.0) 
1,166 (35.5) 
37 (1.1) 
Aetiology  
   Ischaemic  
   Non-ischemic 
 
892 (54.9) 
732 (45.1) 
 
884 (54.1) 
750 (45.9) 
 
1,776 (54.5) 
1,482 (45.5) 
Ethnicity 
   White 
   Non-white 
 
1,085 (69.3) 
480 (30.7) 
 
1,117 (70.9) 
458 (29.1) 
 
2,202 (70.1) 
938 (30.0) 
VO2 peak (ml/kg/min); mean (SD) 15.0 (4.5) 15.1 (4.7) 15.0 (4.6) 
6MWT (metres); mean (SD) 362.6 (109.3) 362.5 (112.1) 362.6 (110.7) 
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Table 12: Characteristics of included trials in the HRQoL and exercise capacity 
analyses 
Study characteristics 
Publication year 
   1990 to 1999 
   2000 to 2009 
   2010 to 2012 
   Unpublished 
 
0 (0) 
9 (64) 
5 (36) 
0 (0) 
Main study location 
   Europe   
   North America* 
 
9 (64) 
5 (36) 
Single study centre 
   Single 
   Multiple  
   Not reported 
 
10 (71.4) 
4 (28.6) 
0 (0) 
Sample size 
   0 to 99 
   100 to 999 
   1000 and over 
 
8 (57) 
5 (36) 
1 (7) 
Duration of latest follow up (weeks); median (range) 
   HRQoL outcomes 
   Exercise capacity outcomes 
 
33 (26 to 104) 
26 (9 to 520) 
Intervention characteristics 
Intervention type 
   Exercise only programs 
   Comprehensive programs 
 
 
9 (64.3) 
5 (35.7) 
Type of exercise 
   Aerobic exercise only 
   Aerobic plus resistance training  
 
10 (71.4) 
4 (28.6) 
Dose of intervention   
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   Duration of intervention (weeks), median (range) 
   Frequency (sessions per week), median (range) 
   Length of exercise session (mins), median (range) 
   Exercise intensity, range 
 
 
24 (4 to 120) 
3 (2 to 6.5) 
30 (15 to 60) 
40-70% peak VO2 
11-15 Borg rating  
Setting 
   Centre-based only 
   Home-based only 
 
9 (64.3) 
5 (35.7) 
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Assessment of study quality and risk of bias 
There was no evidence of significant small study bias for the five outcomes studied (see 
Figure 7). The overall quality of included trials was judged to be moderate to good, with a 
median TESTEX (31) score of 11 (range 9 to 14) out of a maximum score of 15 (see Table 
13Error! Reference source not found.).  The criteria of allocation concealment and physical 
activity monitoring in the control groups were met in only two (19, 61) and three studies, (19, 58, 
66) respectively. The other TESTEX criteria were each met in 50% or more of trials.  
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a. Minnesota Living with Heart Failure (12 months) 
Egger test -1.40, p=0.656                                                                                                                        
 
b. All HRQoL measures  (12 months) 
Egger test -0.72, p=0.577 
0
2
4
6
8
s
ta
n
d
a
rd
 e
rr
o
r 
(e
ff
e
c
t 
s
iz
e
)
-30 -20 -10 0 10
Effect size
0
.1
.2
.3
s
ta
n
d
a
rd
 e
rr
o
r 
(e
ff
e
c
t 
s
iz
e
)
-1 -.5 0 .5
Effect size
76 | P a g e  
 
 
c. Peak VO2, directly reported  (12 months) 
Egger test 0.99, p=0.665 
 
d. 6MWT, directly reported  (12 months) 
Egger test 1.71, p=0.150 
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e. All exercise capacity measures  (12 months) 
Egger test 1.85, p=0.214 
 
Figure 7: Funnel plots for HRQoL and exercise capacity analyses 
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Table 13: Assessment of quality using TESTEX scale of included studies in HRQoL and exercise capacity analysis 
Study (publication 
year) 
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Belardinelli (2012) 1 0 0 1 0 3 1 1 1 0 0 1 9 
Dracup (2007) 1 0 0 1 0 3 1 2 1 1 1 1 10 
Gary (2010) 1 1 0 1 1 3 1 2 1 0 0 0 11 
Giannuzzi (2003) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Hambrecht (2000) 1 1 0 1 0 3 0 2 1 0 1 1 11 
HF-Action (2008) 1 1 1 1 1 3 1 2 1 1 0 1 14 
Jolly (2009) 1 1 1 1 0 2 1 2 1 0 1 1 12 
Mueller (2007) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Nilsson (2008) 1 1 0 1 1 2 1 2 1 0 0 1 11 
Passino (2006) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Witham (2005) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Witham (2012) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Yeh (2011) 1 1 0 1 1 3 1 2 1 1 0 0 12 
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(a) Three points possible 
(b) If ITT was not specifically mentioned, but it was noted that no participants withdrew and all analysed 
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Findings 
Primary analysis  
Compared with control, treatment effects from the one-stage meta-analysis at 12 month 
follow-up showed a significant improvement with ExCR in exercise capacity as assessed by 
6MWT (mean difference: 21.0 metres, 95% CI: 1.57 to 40.4, p=0.034, τ2 = 491, I2 =78%) and 
standardised exercise capacity score (mean difference: 0.27 standard deviation units, 95% CI 
0.11 to 0.43, p=0.001, τ2 =0.08, I2 =91%). No significant difference in VO2peak at 12-months 
was observed: 1.01 (95% CI -0.42 to 2.44, p=0.168, τ2 = 2.17, I2 =94%).  
 
One-stage meta-analysis showed a significant improvement in HRQoL as assessed by the 
MLHFQ at 12-month follow-up:  mean difference: -5.94, 95% CI -1.0 to -10.9, p=0.018, τ2 
=77, I2 =88%), standardised HRQoL score (mean difference: 0.20 standard deviation units. 
95% CI 0.03 to 0.37, p=0.020, τ2 =0.07, I2 =85%). Similar results were seen at 6-months 
follow up (see Forest plots for 6 month follow-up in Figure 8 and 12 month follow-up in 
Figure 9)). Marked statistical heterogeneity (I2 > 70%) was seen for all exercise capacity and 
HRQoL outcomes.  
 
Analyses revealed no consistent interaction between the effect of ExCR and the predefined 
subgroups (gender, ejection fraction, NYHA class, HF aetiology, ethnicity, and baseline 
exercise capacity) for either exercise or HRQoL.  
 
A differential effect of ExCR across ages was observed in the standardised HRQoL analysis, 
with a reduction in HRQoL score (i.e.: an increase in standardised HRQoL score) as age 
increased (0.006 standard deviation units, 95% 0.002 to 0.011, p=0.006). To put this into 
context, based on MLHFQ standard deviation of 24, this equates to a decrease of 1.4 in the 
treatment effect on the MLHFQ score for every 10 years increase in patient age.  
 
Interaction analyses for the one-stage model at 12-month follow-up showed differential 
effects of ExCR dependent by gender, with women showing greater benefit than men for 
each of VO2peak (0.57 ml/kg/min, 95% CI: 0.04 to 1.11, p=0.036) and 6MWT (14.9 metres, 
95% CI: 1.2  to 28.7, p=0.034). Differential effects of ExCR were also seen between ethnic 
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groups, with white patients showing a greater improvement in 6MWT distance compared to 
non-white patients:(14.2 metres, 95% CI: 0.40 to 28.0, p=0.044).  
 
a. Minnesota Living with Heart Failure (MLHFQ) (mean difference)                                                               
 
b. All HRQoL measures (standardised mean difference) 
 
c. Peak VO2, directly reported (mean difference) 
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d. 6MWT (metres), directly reported (mean difference) 
 
e. All exercise capacity measures (standardised mean difference) 
 
Figure 8: Effect of ExCR on HRQoL and exercise capacity at 6 months: two-stage IPD 
meta-analysis 
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a. Minnesota Living with Heart Failure (MLHFQ) (mean difference) 
 
b. All HRQoL measures (standardised mean differences) 
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c. Peak VO2, directly reported (mean difference) 
 
d. 6MWT (metres), directly reported (mean difference) 
 
e. All exercise capacity measures (standardised mean difference) 
 
Figure 9: Effect of ExCR on HRQoL and exercise capacity at 12 months: two-stage IPD 
meta-analysis  
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Secondary analysis  
In the repeated measures analyses for each HRQoL and exercise capacity outcome, a 
significant interaction between ExCR and time was observed (see Figure 10Error! 
Reference source not found.).  In order to visualise comparisons of changes in HRQoL and 
exercise capacity within each subgroup, the effect estimates and associated 95% CI from 
individual subgroup one-stage IPD meta-analyses are shown in Figure 11. The p-value from 
the interaction test in the two-stage IPD meta-analyses are presented alongside these 
estimates. 
Sensitivity analyses  
In sensitivity analyses, the results of the analyses excluding HF-ACTION, were broadly 
consistent with the overall results. (see Tables 14-18). Similar results were found with the 
addition of the study-level aggregate data to the two-stage model at 12 months follow-up. 
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a. Minnesota Living with Heart Failure  (mean 
difference)                                                             
 
b. All HRQoL measures (standardised mean 
difference)                                                 
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c. Peak VO2, directly reported (mean difference)                                                 
 
d. 6MWT, directly reported (mean difference)                                                 
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e. All exercise capacity measures (standardised mean 
difference)                                                 
Figure 10: Effect of ExCR on HRQoL and exercise capacity 
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a. Minnesota Living with Heart Failure (MLHFQ)  
 
b. All HRQoL measures (standardised score) 
 
c. Peak VO2, directly reported  
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d. 6MWT (metres), directly reported   
 
e. All exercise capacity measures (standardised score) 
*although stratified meta-analyses are shown, the interaction P-values are calculated based on 
continuous distribution of age, ejection fraction, and baseline exercise capacity  
Figure 11: Effect of ExCR on HRQoL and exercise capacity across patient subgroups 
(individual subgroup one-stage IPD meta-analyses) 
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Table 14: MLHFQ - overall treatment effect and subgroup (interaction) effects 
 
Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with 
random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU ,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Overall effect -2.85 (-5.85, 
0.14), 
p=0.062 
-1.73 (-4.15, 
0.70), 
p=0.163 
-5.94 (-10.87, -
1.01), p=0.018 
-5.73 (-
12.38, 
0.93), 
p=0.091 
Not applicable to MLHFQ analyses as HF-Action  
only supplied Kansas scores 
Interaction terms 
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Age 
(years) 
0.12 (-0.10, 
0.35), 
p=0.280 
 0.01 (-0.20, 
0.22), p=0.912 
     
Gender 
(male vs 
female) 
-5.31 (-
11.01, 0.39), 
p=0.068 
 -1.49 (-6.95, 
3.96), p=0.592 
     
Ejection 
fraction (%) 
0.22 (-0.14, 
0.58), 
p=0.227 
 0.24 (-0.07, 
0.56), p=0.127 
     
Ejection 
Fraction 
(HFrEF vs 
HFpEF) 
4.06 (-11.0, 
19.1), 
p=0.597 
 8.02 (-3.29, 
19.3), p=0.165 
     
NYHA class  
(NYHA I/II vs 
NYHA III/IV) 
-6.38 (-
12.31, -0.45), 
p=0.035 
 -5.30 (-10.9, 
0.24), p=0.061 
     
HF aetiology 
(ischaemic vs 
non-ischaemic) 
4.67 (-1.65, 
11.0), 
p=0.147 
 2.08 (-3.64, 
7.80), p=0.477 
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Ethnic group  
(white vs non-
white) 
3.15 (-4.31, 
10.6), 
p=0.408 
 5.17 (-2.19, 
12.5), p=0.169 
     
Exercise capacity        
Baseline peak 
VO2 directly 
measured 
0.24 (-0.82, 
1.31), 
p=0.654 
 0.47 (-0.35, 
1.29), p=0.262 
     
Baseline peak 
VO2, directly 
measured and 
predicted 
0.72 (-0.01, 
1.45), 
p=0.053 
 0.62 (-0.02, 
1.26), p=0.058 
     
Peak VO2: peak oxygen uptake
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Table 15: Standardised HRQoL measure- overall treatment effect and subgroup (interaction) effects 
 
Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with 
random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Overall effect -0.11 (-0.16, 
-0.06), 
p<0.001 
-0.10 (-0.15, -
0.05), 
p<0.001 
-0.20 (-0.37, -
0.03), p=0.020 
-0.19 (-
0.38, -0.01), 
p=0.043 
-0.11 (-0.24, 
0.01), 
p=0.069 
-0.08 (-0.18, 
0.02), 
p=0.131 
-0.17 (-0.28, 
-0.07), 
p=0.001 * 
-0.21 (-0.45, 
0.04), 
p=0.106 
Interaction terms 
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Age 
(years) 
0.006 (0.002, 
0.011), 
p=0.006 
 0.001 (-0.004, 
0.005), 
p=0.734 
 0.003 (-
0.007, 0.014), 
p=0.536 
 -0.001 (-
0.011, 
0.008), 
p=0.788 
 
Gender 
(male vs 
female) 
0.050 (-
0.068, 
0.168), 
p=0.407 
 0.018 (-0.105, 
0.140), 
p=0.775 
 -0.223 (-
0.469, 0.024), 
p=0.077 
 -0.106 (-
0.335, 
0.123, 
p=0.365 
 
Ejection 
fraction (%) 
-0.000 (-
0.007, 
0.007), 
p=0.963 
 -0.004 (-0.011, 
0.004), 
p=0.340 
 0.010 (-
0.006, 0.025), 
p=0.225 
 0.010 (-
0.003, 
0.023), 
p=0.150 
 
Ejection 
Fraction 
(HFrEF vs 
HFpEF) 
-0.03 (-0.46, 
0.41), 
p=0.902 
 0.13 (-0.26, 
0.53), p=0.505 
 0.16 (-0.47, 
0.84), 
p=0.581 
 0.34 (-0.14, 
0.81), 
p=0.163 
 
NYHA class  
(NYHA I/II vs 
NYHA III/IV) 
-0.013 (-
0.126, 
0.100), 
p=0.824 
 0.031 (-0.086, 
0.149), 
p=0.599 
 -0.126 (-
0.380, 0.129), 
p=0.334 
 -0.082 (-
0.314, 
0.151), 
p=0.491 
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HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.076 (-
0.036, 
0.187), 
p=0.182 
 0.030 (-0.085, 
0.145), 
p=0.611 
 0.220 (-
0.055, 0.494), 
p=0.117 
 0.080 (-
0.162, 
0.322), 
p=0.517 
 
Ethnic group  
(white vs non-
white) 
0.041 (-
0.079, 
0.161), 
p=0.506 
 0.017 (-0.108, 
0.142), 
p=0.787 
 0.173 (-
0.172, 0.519), 
p=0.325 
 0.243 (-
0.086, 
0.573), 
p=0.147 
 
Exercise capacity        
Baseline peak 
VO2 directly 
measured 
-0.002 (-
0.014, -
0.011), 
p=0.775 
 0.008 (-0.005, 
0.021), 
p=0.230 
 0.012 (-
0.035, 0.059), 
0.612 
 0.021 (-
0.012, 
0.055), 
p=0.216 
 
Baseline peak 
VO2, directly 
measured and 
predicted 
0.000 (-
0.012, 
0.013), 
p=0.956 
 0.008 (-0.004, 
0.021), 
p=0.208 
 0.023 (-
0.010, 0.056), 
p=0.171 
 0.020 (-
0.008, 
0.048), 
p=0.172 
 
Standardised 
scores using 
baseline peak 
N/A as no 
further data 
available 
   N/A as no 
further data 
available 
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VO2, 6MWT, 
ISWT units, 
and watts 
over analysis 
in row above 
over analysis 
in row above 
* Fixed effect on treatment with a random effect on study, due to non-convergence of the random treatment effect model; peak VO2: peak 
oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test. 
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Table 16: Peak VO2 directly measured - overall treatment effect and subgroup (interaction) effects 
 
Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with 
random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with random 
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Overall effect 0.62 (-0.82, 
2.07), 
p=0.397 
0.69 (-0.24, 
1.62), 
p=0.145 
1.01 (-0.42, 
2.44), p=0.168 
1.14 (-0.05, 
2.34), 
p=0.061 
0.71 (-1.10, 
2.52), 
p=0.444 
0.77 (-0.73, 
2.28), 
p=0.315 
1.15 (-0.60, 
2.90), 
p=0.196 
1.26 (-0.31, 
2.82), 
p=0.115 
Interactions terms 
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Age 
(years) 
0.00 (-0.02, 
0.02), 
p=0.980 
 -0.00 (-0.02, 
0.14), p=0.646 
 -0.01 (-0.07, 
0.04), 
p=0.628 
 -0.02 (-0.06, 
0.03), 
p=0.415 
 
Gender 
(male vs 
female) 
-0.25 (-0.78, 
0.27), 
p=0.345 
 -0.57 (-1.11, -
0.04), p=0.036 
 -0.67 (-2.47, 
1.14), 
p=0.468 
 -0.42 (-1.80, 
0.95), 
p=0.549 
 
Ejection 
fraction (%) 
0.03 (0.00, 
0.06), 
p=0.034 
 0.02 (-0.01, 
0.05), p=0.157 
 0.05 (-0.04, 
0.13), 
p=0.280 
 0.03 (-0.04, 
0.11), 
p=0.349 
 
Ejection 
Fraction 
(HFrEF vs 
HFpEF) 
0.07 (-1.88, 
2.01), 
p=0.947 
 -0.13 (-2.07, 
1.81), p=0.897 
 -1.34 (-2.42, 
5.09), 
p=0.485 
 -0.19 (-3.34, 
2.97), 
p=0.907 
 
NYHA class  
(NYHA I/II vs 
NYHA III/IV) 
-0.10 (-0.58, 
0.38), 
p=0.687 
 -0.25 (-0.75, 
0.24), p=0.318 
 -0.50 (-2.13, 
1.13), 
p=0.549 
 -0.75 (-1.95, 
0.46), 
p=0.224 
 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.02 (-0.44, 
0.47), 
p=0.945 
 -0.13 (-0.60, 
0.34), p=0.577 
 -0.63 (-2.04, 
0.79), 
p=0.386 
 -0.24 (-1.39, 
0.91), 
p=0.683 
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Ethnic group  
(white vs non-
white) 
-0.19 (-0.66, 
0.29), 
p=0.447 
 -0.07 (-0.58, 
0.45), p=0.800 
 -0.47 (-2.36, 
1.43), 
p=0.628 
 0.16 (-1.71, 
2.03), 
p=0.870 
 
Exercise capacity        
Baseline peak 
VO2 directly 
measured 
0.01 (-0.04, 
0.06), 
p=0.719 
 0.03 (-0.03, 
0.08), p=0.332 
 -0.06 (-0.21, 
0.09), 
p=0.435 
 -0.04 (-0.17, 
0.10), 
p=0.602 
 
Baseline peak 
VO2, directly 
measured and 
predicted 
0.01 (-0.04, 
0.06), 
p=0.702 
 0.03 (-0.02, 
0.08), p=0.299  
 
 -0.06 (-0.21, 
0.09), 
p=0.452 
 
 -0.03 (-0.16, 
0.10), 
p=0.660 
 
 
Peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test. 
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Table 17: 6MWT directly measured - overall treatment effect and subgroup (interaction) effects 
 
Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with 
random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with random 
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Overall effect 22.1 (1.87, 
42.3), 
p=0.032 
24.4 (6.13, 
42.6), 
p=0.009 
21.0 (1.57, 
40.4), p=0.034 
24.0 (5.30, 
42.7), 
p=0.012 
22.1 (-1.64, 
45.8), 
p=0.068 
27.9 (1.25, 
54.6), 
p=0.040 
24.0 (1.25, 
46.7), 
p=0.039 
29.0 (3.05, 
55.0), 
p=0.029 
Interaction terms 
105 | P a g e  
 
Age 
(years) 
0.01 (-0.49, 
0.50), 
p=0.973 
 -0.03 (-0.56, 
0.50), p=0.911 
 0.45 (-0.81, 
1.72), 
p=0.482 
 0.97 (-0.23, 
2.17), 
p=0.115 
 
Gender 
(male vs 
female) 
-10.7 (-23.6, 
2.26), 
p=0.106 
 -14.9 (-28.7, -
1.16), p=0.034 
 -19.7 (-47.3, 
7.92), 
p=0.162 
 -13.5 (-39.9, 
12.9), 
p=0.317 
 
Ejection 
fraction (%) 
0.34 (-0.46, 
1.14), 
p=0.399 
 0.21 (-0.64, 
1.06), p=0.634 
 1.05 (-0.78, 
2.88), 
p=0.262 
 0.04 (-1.69, 
1.77), 
p=0.963 
 
Ejection 
fraction 
(HFrEF vs 
HFpEF) 
0.68 (-47.8, 
49.2), 
p=0.978 
 15.4 (-36.3, 
67.0), p=0.560 
 13.8 (-6.09, 
88.6), 
p=0.717 
 14.7 (-56.1, 
85.4), 
p=0.685 
 
NYHA class  
(NYHA I/II vs 
NYHA III/IV) 
-1.81 (-14.3, 
10.6), 
p=0.776 
 1.31 (-12.0, 
14.6), p=0.847 
 -5.90 (-34.6, 
22.8), 
p=0.687 
 -8.14 (-35.7, 
19.4), 
p=0.563 
 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
3.73 (-8.26, 
15.7), 
p=0.542 
 -4.30 (-17.1, 
8.51), p=0.510 
 37.9 (9.34, 
66.4), 
p=0.009 
 26.9 (-0.13, 
54.0), 
p=0.051 
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Ethnic group  
(white vs non-
white) 
10.46 (-2.55, 
23.5), 
p=0.115 
 14.2 (0.40, 
28.0), p=0.044 
 -20.7 (-60.5, 
19.0), 
p=0.307 
 8.34 (-29.5, 
46.1), 
p=0.665 
 
Exercise capacity        
Baseline 
6MWT directly 
measured 
-0.05 (-0.11, 
0.01), 
p=0.079 
 0.19 (-0.08, 
0.46), p=0.176 
 -0.06 (-0.18, 
0.06), 
p=0.321 
 -0.05 (-0.16, 
0.07), 
p=0.421 
 
6MWT: 6-minute walk test. 
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Table 18: Standardised exercise capacity score - overall treatment effect and subgroup (interaction) effects 
 
Primary analyses Sensitivity analyses, 
excluding HF-Action 
  One-stage 
model, 6 
months FU, 
with 
random  
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with random 
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 6 
months FU, 
with random  
treatment 
effect  
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model, 6 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
One-stage 
model, 12 
months FU,  
with 
random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Two-stage 
model,  
12 months 
FU,  
with random 
treatment 
effect 
Mean 
difference 
(95% CI) 
p-value 
Overall effect 0.230 (0.067, 
0.392), 
p=0.006 
0.256 (0.116, 
0.396), 
p<0.001 
0.268 (0.110, 
0.426), 
p=0.001 
0.302 
(0.142, 
0.462), 
p<0.001 
0.256 (0.079, 
0.433), 
p=0.005 
0.278 
(0.105, 
0.451), 
p=0.002 
0.298 
(0.125, 
0.471), 
p=0.001 
0.324 (0.150, 
0.497), 
p<0.001 
Interaction terms 
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Age 
(years) 
0.001 (-
0.003, 
0.004), 
p=0.758 
 -0.001 (-0.005, 
0.003), 
p=0.636 
 0.003 (-
0.008, 0.014), 
p=0.565 
 -0.000 (-
0.010, 
0.009), 
p=0.948 
 
Gender 
(male vs 
female) 
-0.063 (-
0.157, 
0.319), 
p=0.194 
 -0.096 (-0.197, 
0.006), 
p=0.065 
 -0.066 (-
0.250, 0.118), 
p=0.484 
 -0.065 (-
0.240, 
0.110), 
p=0.464 
 
Ejection 
fraction (%) 
0.007 (0.001, 
0.012), 
p=0.021 
 0.005 (-0.001, 
0.011), 
p=0.108 
 0.008 (-
0.003, 0.019), 
p=0.131 
 0.008 (-
0.003, 
0.018), 
p=0.169 
 
Ejection 
Fraction 
(HFrEF vs 
HFpEF) 
0.11 (-0.20, 
0.43), 
p=0.487 
 0.06 (-0.28, 
0.40), p=0.733 
 0.21 (-0.23, 
0.65), 
p=0.348 
 0.06 (-0.36, 
0.49), 
p=0.766 
 
NYHA class  
(NYHA I/II vs 
NYHA III/IV) 
-0.010 (-
0.098, 
0.079), 
p=0.826 
 -0.043 (-0.138, 
0.052), 
p=0.377 
 -0.011 (-
0.184, 0.162), 
p=0.900 
 -0.061 (-
0.224, 
0.101), 
p=0.459 
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HF aetiology 
(ischaemic vs 
non-ischaemic) 
0.012 (-
0.074, 
0.098), 
p=0.783 
 0.024 (-0.070, 
0.117), 
p=0.620 
 0.035 (-
0.143, 0.213), 
p=0.701 
 0.049 (-
0.121, 
0.219), 
p=0.573 
 
Ethnic group  
(white vs non-
white) 
-0.064 (-
0.159, 
0.031), 
p=0.187 
 0.018 (-0.088, 
0.124), 
p=0.741 
 -0.096 (-
0.352, 0.160), 
p=0.461 
 0.078 (-
0.195, 
0.351), 
p=0.577 
 
Exercise capacity        
Standardised 
scores using 
baseline peak 
VO2, 6MWT, 
ISWT units, 
and watts 
-0.025 (-
0.066, 
0.017), 
p=0.240 
 -0.017 (-0.048, 
0.508), 
p=0.105 
 -0.070 (-
0.147, 0.007), 
p=0.077 
 -0.052 (-
0.129, 
0.026), 
p=0.191 
 
Peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test. 
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Chapter 7: Results from surrogate analysis 
Inclusion of trials in the ExTraMATCH II Surrogate analyses 
All 19 trials from the ExTraMATCH II study were eligible for analysis here if they provided 
the required data (as detailed in the Methods section above). Only 10 trials (19, 51, 58, 61-67) 
provided data for the surrogate analyses. Figure 12Error! Reference source not found. 
summarises the availability of studies and patient data for exercise capacity and the patient-
relevant outcomes of mortality, hospitalisation, and HRQoL.   
 
Characteristics of included patients and trials 
Across ExCR and control groups, patient baseline characteristics were well balanced (see 
Table 19Error! Reference source not found.). Patients had mean age of 62 years and the 
majority were male (73%). The mean baseline left-ventricular ejection fraction was 26%; 
most patients were in NYHA functional class II (63%) or III (34%).  Studies were published 
between 2000 and 2012 from a range of geographical locations (see Table 20Error! 
Reference source not found.). Sample size was typically small and ranged from 50 to 2130 
patients. All trials included ExCR based on an aerobic exercise intervention. The dose of 
ExCR ranged widely across studies: average session duration of 15 to 60 minutes; 2 to 7 
sessions/week; exercise intensity equivalent of 40 to 70% VO2peak, delivered over a duration 
of 4 to 120 weeks. The change in exercise capacity and final patient-relevant outcomes for 
each included studies is shown in Table 21Error! Reference source not found..  
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Figure 12: PRISMA flow diagram summarising selection of studies for ExTraMATCH II surrogate analysis 
ExTraMATCH II IPD meta-analysis 
n=19 trials provided data (n=3,990 patients) 
Change in Minnesota Living with Heart Failure score at 12 month follow-up 
(6 trials = 626 patients) 
Δ VO2 peak direct – 3 trials (252 patients) 
Δ 6MWT – 4 trials (362 patients) 
Δ VO2 peak direct and indirect – 6 trials (580 patients) 
All-cause mortality 
(17 trials = 3,782 patients) 
Δ VO2 peak direct– 6 trials (2,112 patients) 
Δ 6MWT – 6 trials (2,154 patients) 
Δ VO2 peak direct and indirect– – 10 trials (2,656 patients) 
All-cause hospitalisation 
(11 trials = 3,190 patients) 
Δ VO2 peak direct – 4 trials (1,980 patients) 
Δ 6MWT – 5 trials (2,078 patients) 
Δ VO2 peak direct and indirect – 7 trials (2,448 patients) 
Change in Exercise Capacity measurements at 6 month follow-up 
Δ VO2 peak direct – 6 trials (2,112 patients); Δ 6MWT – 6 trials (2,154 patients); Δ VO2 peak direct and indirect– 10 trials (2,656 patients) 
Change in Health-related Quality of life (SMD) at 12 month follow-up 
(8 trials = 2,643 patients) 
Δ VO2 peak direct and indirect – 4 trials (1,949 patients) 
Δ 6MWT – 6 trials (2,108 patients) 
Δ VO2 peak direct and indirect– 8 trials (2,476 patients) 
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Table 19: Baseline characteristics of patients in surrogate analyses 
  
ExCR group 
(n=1,345) 
Control group 
(n= 1,311) 
All patients 
(n= 2,656) 
Age (years), mean (SD) 61.2 (13.0) 61.6 (13.4) 61.39 (13.19) 
Gender (male), n (%) 970 (72.1) 973 (74.2) 1,943 (73.2) 
Baseline ejection fraction; mean 
(SD) 
26.0 (7.9) 26.2 (7.6) 26.1 (7.8) 
NYHA class, n (%) 
    Class I 
    Class II 
    Class III 
    Class IV 
 
13 (1) 
834 (62) 
485 (36) 
13 (1) 
 
27 (2) 
861 (64) 
444 (33) 
13 (1) 
 
27 (2) 
848 (63) 
457 (34) 
13 (1) 
Aetiology, ischemic, n (%)  713 (53) 708 (54%) 1,421 (54) 
Ethnicity, white (%) 914 (70) 908 (71) 1,822 (70) 
VO2peak (ml/kg/min), mean (SD) 15.1 (4.6) 15.2 (4.8) 15.1 (4.7) 
6MWT (metres), mean (SD) 368 (108) 366 (110) 367 (109) 
6MWT: six minute walk test; NYHA: New York Heart Association;  
VO2peak: peak oxygen uptake
  
Table 20: Characteristics of included studies and interventions in surrogate analyses 
Study characteristics 
Publication year, n (%) 
   2000 to 2009 
   2010 to 2012 
 
8 (80) 
2 (20) 
Main study location, n (%) 
   Europe   
   North America (1) 
 
6 (60) 
4 (40) 
Single study centre, n (%) 
   Single 
   Multiple  
 
7 (70) 
3 (30) 
Sample size, n (%) 
   0 to 99 
   100 to 999 
   1000 and over 
 
5 (50) 
4 (40) 
1 (10) 
Duration of latest follow up (weeks); median (range) 10.5 (6 to 30) 
Intervention characteristics 
Type of exercise n (%) 
   Aerobic exercise only 
   Aerobic plus resistance training  
 
6 (60) 
4 (40) 
Dose of intervention  
   Duration of intervention (weeks), median (range) 
   Frequency (sessions per week), median (range) 
   Length of exercise session (mins), median (range) 
   Exercise intensity, range 
 
 
24 (4 to 120) 
2.75 (2.5 to 6.5) 
30 (15 to 60) 
40 to 70% VO2peak 
11 to 15 Borg rating  
Setting, n (%) 
   Centre-based only 
   Home-based only 
Both home and centre-based 
 
3 (30) 
2 (20) 
5 (50) 
 (1) HF-ACTION trial also includes French patients 
  
HRQoL: health-related quality of life; VO2peak: peak oxygen uptake 
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Table 21: Change in exercise capacity and final patient-relevant outcomes for each included study 
Study (Year) 
ΔVO2peak 
direct 
(ml/kg/min) 
mean difference  
Δ6MWT 
(metres)  mean 
difference 
ΔVO2peak 
direct and 
indirect 
(ml/kg/min)  
mean 
difference 
ΔMLHFQ  mean 
difference 
ΔHRQoL any 
validated 
measure  mean 
difference 
All-cause 
mortality HR  
 
All-cause 
hospital 
admission 
HR 
Dracup (2007) 0.04 (-1.26 to 
1.34) 
5.19 (-28.39 to 
38.78) 
0.15 (-0.91 to 
1.21) 
-2.19 (-9.09 to 
4.70) 
-0.15 (-0.44 to 
0.15) 
1.16 (0.51 to 
2.64) 
1.31 (0.84 to 
2.05 
Hambrecht 
(2000) 
-2.16 (-4.43 to 
0.10) 
 -2.16 (-4.43 to 
0.10) 
  0.93 (0.13 to 
6.65) 
0.97 (0.14 to 
6.88) 
HF-ACTION 
(2009) 
0.47 (0.24 to 
0.71) 
18.14 (11.60 to 
24.68) 
0.43 (0.20 to 
0.66) 
 -0.10 (-0.17 to -
0.04) 
0.92 (0.75 to 
1.13) 
0.93 (0.83 to 
1.03) 
Jolly (2009)   0.57 (-0.15 to 
1.29) 
1.35 (-4.02 to 
6.71) 
0.07 (-0.16 to 
0.30) 
1.62 (0.45 to 
5.78) 
0.72 (0.36 to 
1.42) 
Mueller 
(2007) 
4.47 (2.35 to 
6.60) 
 4.48 (2.35 to 
6.60) 
  0.78 (0.33 to 
1.85) 
 
Nilsson 
(2008) 
 77.22 (47.58 to 
106.87) 
1.78 (1.09 to 
2.46) 
-6.78 (-13.05 to -
0.50) 
-0.30 (-0.57 to -
0.02) 
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Passino 
(2006) 
1.57 (0.66 to 
2.49) 
 1.57 (0.66 to 
2.49) 
-23.41 (-28.87 to -
17.94) 
-0.82 (-1.01 to -
0.63) 
0.48 (0.23 to 
0.97) 
 
Witham 
(2005) 
 5.18 (-17.41 to 
27.76) 
0.12 (-0.40 to 
0.64) 
 0.04 (-0.40 to 
0.49) 
0.29 (0.03 to 
2.84) 
1.03 (0.41 to 
2.60) 
Witham 
(2012) 
 -2.03 (-26.14 to 
22.08) 
-0.05 (-0.60 to 
0.51) 
0.86 (-3.13 to 
4.84) 
0.04 (-0.16 to 
0.24) 
2.09 (0.19 to 
23.03) 
0.94 (0.39 to 
2.28) 
Yeh (2011) -0.02 (-1.02 to 
0.98) 
1.25 (-24.71 to 
27.20) 
-0.17 (-1.16 to 
0.82) 
-3.09 (-9.31 to 
3.14) 
-0.16 (-0.43 to 
0.12) 
 0.57 (0.14 to 
2.38) 
Pooled 
results  
0.69 (-0.24 to 
1.62) 
p=0.145 
I2 = 80.4% 
16.69 (-1.08 to 
34.36) 
p=0.066 
I2 = 76.5% 
0.61 (0.10 to 
1.11) 
p=0.019 
I2 = 80.3% 
-5.53 (-13.27 to 
2.21) 
p=0.162 
I2 = 91.5% 
-0.18 (-0.39 to 
0.02) 
p=0.084 
I2 = 87.9% 
0.83 (0.67 to 
1.04) 
p=0.107 
I2 = 25.7% 
0.90 (0.76 to 
1.06) 
p=0.210 
I2 = 12.4% 
ΔMLHFQ: change in Minnesota Living with Heart Failure; ΔHRQoL: change in health-related quality of life; 
ΔVO2peak: change in peak oxygen uptake; Δ6MWT: change in 6-minute walk test 
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Assessment of study quality and risk of bias 
The overall quality of included trials was judged to be moderate to good, with a median 
TESTEX (31) score of 11 (range 10 to 14) out of a maximum score of 15 (see Table 22Error! 
Reference source not found.).   
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Table 22: Assessment of quality using TESTEX scale of included studies in surrogate analyses 
Study  
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Dracup (2007) 1 0 0 1 0 3 1 2 1 1 1 1 10 
Hambrecht (2000) 1 1 0 1 0 3 0 2 1 0 1 1 11 
HF-ACTION (2008) 1 1 1 1 1 3 1 2 1 1 0 1 14 
Jolly (2009) 1 1 1 1 0 2 1 2 1 0 1 1 12 
Mueller (2007) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Nilsson (2008) 1 1 0 1 1 2 1 2 1 0 0 1 11 
Passino (2006) 1 0 0 1 0 2 1 2 1 0 1 1 10 
Witham (2005) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Witham (2012) 1 1 0 1 1 3 1 2 1 0 1 0 12 
Yeh (2011) 1 1 0 1 1 3 1 2 1 1 0 0 12 
(1) Three points possible; (2) If ITT was not specifically mentioned, but it was noted that no participants withdrew and all analysed 
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Findings 
Mediation analysis 
The four criteria which must be satisfied in order to establish that change in exercise capacity 
is a mediator of mortality, hospitalisation and change in HRQoL are listed in Table 23Error! 
Reference source not found.. First, mean improvements were seen in all exercise capacity 
metrics with ExCR compared to control, although none reached statistical significance at 
p<0.05. Second, greater differences in exercise capacity significantly reduced the risk of 
mortality and hospitalisation and was associated with a larger gain in HRQoL. Third, 
although ExCR decreased both the risk of mortality and hospitalisation and was also 
associated with a larger gain in HRQoL, there was no statistically significant difference 
compared to control. Finally, the effect of ExCR versus control on final patient-relevant 
outcomes was attenuated by adding Δ6MWT and ΔVO2peak (directly and indirectly 
measured) into the model. No attenuation was seen with the addition of ΔVO2peak when 
measured directly.  
Meta-analytic regression: R2 and surrogate threshold effect  
Regression coefficients of determination (R2) and correlation coefficients (ρ) between the 
change in exercise capacity and hospitalisation were poor (R2trial <50% and ρ<0.50). 
Moderate to good levels of correlation (R2trial >50% and ρ>0.50) between exercise capacity 
VO2peak and 6MWT with mortality and HRQoL were seen (Table 24Error! Reference 
source not found.). STE for MLHFQ ranged from an increase of 1.6 to 4.6 ml/kg/min for 
VO2peak. STE was not estimable for 6MWT. Negative correlation coefficients indicate that 
larger ExCR effects on exercise capacity are associated with larger ExCR effects on mortality 
and HRQoL. Figure 13Error! Reference source not found., Figure 14 Error! Reference 
source not found.and Figure 15Error! Reference source not found. illustrate the results of 
our meta-regression and STE analysis.  
 
Small study bias 
There was no evidence of significant small study bias as shown by the funnel plots (see 
Figure 16Error! Reference source not found.) or Egger’s test p-values for any of the 
exercise capacity outcomes (ΔVO2peak direct, p = 0.699; Δ6MWT, p = 0.93; ΔVO2peak 
120 | P a g e  
 
direct and indirect, p = 0.553) or the four patient-relevant final outcomes (ΔMLHFQ, p = 
0.607; ΔHRQoL outcomes, p = 0.659; mortality, p = 0.745; hospitalisation, p = 0.733). 
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Table 23: Criteria to establish change in exercise capacity as a mediator in the relationship between treatment effect on patient-relevant 
final outcomes 
 
ΔVO2 peak direct 
(ml/kg/min)  
Δ6MWT (metres)  
  
ΔVO2 peak direct and 
indirect (ml/kg/min) 
Criteria 1 
1. Treatment assignment has a significant effect 
on exercise capacity 
0.61 (95%CI, -0.89 to 
2.11) 
14.61 (95% CI, -6.16 to 
35.37) 
0.58 (95% CI, -0.35 to 
1.51) 
Criteria 2 
2. Exercise capacity has a significant effect on 
ΔMLHFQ  
-1.64 (95% CI, -2.57 to -
0.71) 
-0.06 (95% CI, -0.08 to -0.03) -1.80 (95% CI, -2.77 to -
0.83) 
2. Exercise capacity has a significant effect on 
ΔHRQoL all measures (standard deviation units)  
-0.06 (95% CI, -0.08 to -
0.04) 
-0.002 (95% CI, -0.003 to -
0.001) 
-0.07 (95% CI, -0.08 to -
0.05) 
2. Exercise capacity has a significant effect on 
all-cause mortality HR 
0.88 (95% CI, 0.84 to 
0.92) 
0.997 (95% CI, 0.995 to 
0.998) 
0.88 (95% CI, 0.84 to 
0.92) 
2. Exercise capacity has a significant effect on 
all-cause hospital admission HR 
0.93 (95% CI, 0.91 to 
0.96) 
0.998 (95% CI, 0.997 to 
0.999) 
0.94 (95% CI, 0.92 to 
0.96) 
Criteria 3 
3. Treatment assignment has a significant effect on patient-relevant final outcomes: 
ΔMLHFQ : -5.84 (95%CI, -11.96 to 0.77) 
ΔHRQoL: all outcomes (standard deviation units):-0.22 (95% CI, -0.38 to -0.07)  
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All-cause mortality HR: 0.85 (95% CI, 0.73 to 0.99) 
All-cause hospital admission HR: 0.91 (95% CI, 0.83 to 1.00) 
Criteria 4* 
4. The effect of treatment assignment on 
ΔMLHFQ is attenuated when the change in 
exercise capacity is added to the model 
-8.28 (95% CI, -18.56 to 
2.01) 
-1.77 (95% CI, -4.76 to 1.23) -4.70 (95% CI, -10.81 to 
1.40) 
4. The effect of treatment assignment on 
ΔHRQoL all outcomes is attenuated when the 
change in exercise capacity is added to the model 
-0.28 (95% CI, -0.56 to -
0.01) 
-0.05 (95% CI, -0.12 to 0.01) -0.17 (95% CI, -0.31 to -
0.02) 
4. The effect of treatment assignment on all-
cause mortality HR is attenuated when the 
change in exercise capacity is added to the model 
0.99 (95% CI, 0.79 to 
1.24) 
1.00 (95% CI, 0.81 to 1.24) 1.01 (95% CI, 0.83 to 
1.22) 
4. The effect of treatment assignment on all-
cause hospital admission HR is attenuated when 
the change exercise capacity is added to the 
model 
0.93 (95% CI, 0.82 to 
1.04) 
0.97 (95% CI, 0.86 to 1.09) 0.95 (95% CI, 0.85 to 
1.06) 
HR: hazard ratio; ΔMLHFQ: change in Minnesota Living with Heart Failure Questionnaire; ΔHRQoL: change in health-related quality of life; 
ΔVO2 peak: change in peak oxygen uptake; Δ6MWT: change in 6-minute walk test; * mediator-adjusted coefficient
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Table 24: Surrogacy metrics for change in exercise capacity and final outcomes 
 
ΔVO2 peak direct 
(ml/kg/min) 
Δ6MWT (metres)  
  
ΔVO2 peak direct and 
indirect (ml/kg/min) 
ΔMLHFQ  R2trial     94% 
ρ        -0.80 
STE 2 ml/kg/min 
R2trial     65% 
ρ       -0.90** 
STE not estimable 
R2trial      54% 
ρ         -0.64 
STE 3.2 ml/kg/min 
ΔHRQoL all outcomes (standard deviation units) R2trial     81% 
ρ       -0.60 
STE 1.6 ml/kg/min 
R2trial     54% 
ρ       -0.57  
STE not estimable 
R2trial      62% 
ρ        -0.53 
STE 2 ml/kg/min 
All-cause mortality HR R2trial     21% 
ρ       -0.89** 
STE 4.6 ml/kg/min 
R2trial     1% 
ρ        -0.20 
STE not estimable 
R2trial      7% 
ρ        -0.31 
STE not estimable 
All-cause hospital admission HR 
R2trial     26% 
ρ       -0.20 
STE 1.8 ml/kg/min 
R2trial     9% 
ρ       -0.03 
STE 38 m 
R2trial      14% 
ρ        -0.21 
STE 1.8 ml/kg/min 
HR: hazard ratio; ΔMLHFQ: change in Minnesota Living with Heart Failure Questionnaire; ΔHRQoL: change in health-related quality of life; 
ΔVO2peak: change in peak oxygen uptake; Δ6MWT: change in 6-minute walk test; STE: surrogate threshold effect 
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Circles represent trial-level treatment effects, with sizes proportionate to study weights (based 
on inverse variance weighting). Solid grey lines correspond to the bounds of the 95% 
prediction interval for the true effect on the final outcomes in a new study.  
HR = hazard ratio; HRQoL = health-related quality of life; MLHFQ = Minnesota Living with 
Heart Failure Questionnaire; SMD = standardised mean difference. 
Figure 13: Regression analyses showing the relationship between ΔVO2peak direct at 6 
month follow-up versus log(HR) of all-cause mortality and all-cause hospitalisation, and 
ΔVO2peak direct versus ΔMLHFQ and ΔHRQoL all outcomes 
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Circles represent trial-level treatment effects, with sizes proportionate to study weights (based 
on inverse variance weighting). Solid grey lines correspond to the bounds of the 95% 
prediction interval for the true effect on the final outcomes in a new study.  
HR = hazard ratio; HRQoL = health-related quality of life; MLHFQ = Minnesota Living with 
Heart Failure Questionnaire; SMD = standardised mean difference. 
Figure 14: Regression analyses showing the relationship between Δ6MWT at 6 months 
follow-up versus log(HR) of all-cause mortality and all-cause hospitalisation, and 
Δ6MWT versus ΔMLHFQ and ΔHRQoL all outcomes 
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Circles represent trial-level treatment effects, with sizes proportionate to study weights (based 
on inverse variance weighting). Solid grey lines correspond to the bounds of the 95% 
prediction interval for the true effect on the final outcomes in a new study.  
HR = hazard ratio; HRQoL = health-related quality of life; MLHFQ = Minnesota Living with 
Heart Failure Questionnaire; SMD = standardised mean difference. 
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Figure 15: Regression analyses showing the relationship between ΔVO2peak direct and 
indirect versus log(HR) of all-cause mortality and all-cause hospitalisation, and 
ΔVO2peak direct and indirect versus ΔMLHFQ and ΔHRQoL all outcomes 
 
a. VO2peak 
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b. 6MWT 
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c. Converted exercise capacity score 
 
d. HRQoL 
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e. MLHFQ 
 
f. Mortality 
 
131 | P a g e  
 
g. Hospitalisation 
Figure 16: Funnel Plots for surrogate analysis 
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Chapter 8: Discussion 
The ExTraMATCH II project is a meta-analysis of IPD from HF patients recruited to RCTs 
conducted worldwide that sought to determine which HF patient subgroups benefit most from 
ExCR and assess the suitability of exercise capacity as surrogate endpoint. 
 
Summary of findings 
Of the 37 eligible trials, 19 contributed data to the IPD meta-analysis – 18 trials (3912 
patients) to the clinical events (mortality and hospitalisation) analysis, 13 trials (3332 
patients) to exercise capacity and HRQoL analysis, and 10 trials (2,656  patients) to the 
exercise capacity mediational/surrogate endpoint analysis. 
 
Patient characteristics at baseline were well balanced between ExCR and control patients. 
The majority of patients were male (74%), with a mean age of 61 years and with HFrEF 
(mean left-ventricular ejection fraction: 26.9%), and in NYHA functional class II (59%) or III 
(38%).  Trials from Europe and North America were published between 1990 and 2012. 
Sample size ranged from 50 to 2130 patients. All trials evaluated an aerobic exercise 
intervention, which was most commonly delivered in either an exclusively centre-based 
setting or a centre-based setting in combination with some home exercise sessions. The dose 
of exercise training ranged widely across trials. ExCR was delivered over a period of 15 to 90 
weeks, with between 2 and 7 sessions per week; median session duration was between 4 and 
120 minutes (including warm-up and cool-down). The intensity of exercise ranged between 
50 to 85% peak VO2. The overall quality of included trials was judged to be moderate to 
good, with a median TESTEX score of 11 (range 9 to 14) out of a maximum score of 15.   
Compared to no exercise control, ExCR did not have a statistically significant effect on the 
risk of mortality and hospitalisation. However, uncertainty around effect estimates precludes 
drawing definitive conclusions for these event outcomes. In contrast, ExCR was found to 
significantly improve both exercise capacity and HRQoL, the improvement in MLHFQ being 
also clinically important (i.e. a mean reduction ≥5 points). (74) We found no consistent 
differences in ExCR effects across patient subgroups (age, sex, ethnicity, NYHA functional 
class, ischaemic aetiology, ejection fraction, and baseline exercise capacity) across of 
mortality, hospitalisation, exercise capacity or HRQoL. Our validation of exercise capacity as 
a putative surrogate endpoint for patient-relevant outcomes (mortality, hospitalisation, and 
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HRQoL) was limited by access to a small number of trials that were able to contribute 
suitable patient level data. Although, subject to considerably statistical uncertainty, our 
results provide indicative evidence that VO2peak and 6MWT may be suitable surrogate 
endpoints for the treatment effect of ExCR on final outcomes in HF.  
 
Comparison to existing evidence 
Our finding of a lack of consistent evidence for HF patient subgroup effects of ExCR agrees 
with both the previous ExTraMATCH and Cochrane 2014 analyses. (10, 18) However, these 
two previous studies had major limitations that are likely to have limited their ability to detect 
subgroup effects. ExTraMATCH included data on only 801 HF patients and observed 88 
deaths and 300 patients with a composite outcome of death or hospitalisation, and therefore 
lacked statistical power. Using meta-regression analysis, the 2014 Cochrane review found no 
association between trial level patient characteristics and ExCR. However, meta-regression 
analysis is highly prone to study level confounding (ecological fallacy) and should be 
interpreted with great caution. (75) 
 
Our findings are also consistent with the IPD subgroup analyses from the multicentre HF-
ACTION trial. The HF-ACTION investigators reported no significant interaction effect of 
exercise training intervention on their composite primary outcome (all-cause mortality or 
hospitalisation) and subgroups of age (≤70 vs. > 70 years), gender, race (white vs. non-
white), HF aetiology (ischaemic vs. non ischaemic), ejection fraction (≤25% vs. >25%), or 
NHYA class (II vs. III/IV).(19) A post hoc analysis by HF ACTION investigators, found a 
significant (adjusted p = 0.02) interaction between ExCR and the change in 6MWT with 
ExCR and ethnicity (+26 metres in black patients vs +11 metres in white patients), consistent 
with the current study. (76) 
 
Our validation study of the suitability of exercise as surrogate outcome, albeit uncertain, are 
broadly in agreement with our recent study based on a trial level meta-analyses. (77)   
 
Strengths and limitations 
The ExTraMATCH-II project has a number of strengths. Our IPD meta-analysis is the largest 
to date and has greater power to detect any differential treatment effect across groups than 
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single trials or aggregate meta-analysis. We were able to standardise the handling and 
analysis of time to event outcomes and continuous outcomes across trials. We found no 
evidence of publication bias. The project was conducted and reported in accordance with 
current IPD guidance and Preferred Reporting Items for a Systematic Review and Meta-
analysis of Individual Participant Data (PRISMA IPD) statement. (21, 78) 
 
Whilst systematic reviews and meta-analyses of IPD from randomised trials are recognised as 
the gold standard for assessing intervention effects (79) our study has a number of limitations. 
First, there was a lack consistency in how included trials with IPD in our analyses defined 
and collected the outcomes of interest, i.e. time to event for death and hospitalisation, 
exercise capacity and HRQoL. We made considerable efforts to contact study authors in 
order to clarify issues around the definition of outcomes, especially HF-related mortality and 
hospitalisations. Although we were able to resolve data issues in many cases, we recognise 
that a lack of consistency in outcome definition across included trials may exist, weakening 
the strength of our conclusions. Second, we were not able to obtain IPD from all includable 
trials for all outcomes - not all investigator for the trials that met our inclusion criteria were 
able to provide IPD and of the trials that did provide IPD, not all collected the outcomes of 
interest. For example, the large National Institutes of Health (NIH) funded US multicentre 
HF-ACTION trial did not collect HF-specific hospitalisation (19), thus reducing our statistical 
power for this outcome. Third, we did not seek patient level data on ‘ExCR dose’, i.e. 
adherence according to exercise training duration, frequency and intensity undertaken by an 
individual patient. Using IPD from HF-ACTION, Keteyian et al found exercise volume 
(defined as metabolic equivalent of task (MET)-hour per week) to be a predictor for the 
composite outcome of all-cause mortality or hospitalisation (p=0.03) (80) Fourth, there were 
high levels of statistical heterogeneity for both exercise capacity and HRQoL outcomes. This 
heterogeneity may well have reflected the variation in ExCR interventions across the 
included trials. Fifth, our analysis is based on randomised trials identified by literature 
searches up to 2013 and therefore did not include IPD from more recent trials that may have 
met the inclusion criteria of this study.   
 
Finally, in terms of our surrogate validation analysis a particular limitation was the proportion 
of included trials that provided patient level data on both exercise capacity and patient-
relevant outcomes. Of the 19 trials (3,990 patients) that met our inclusion criteria, only a 
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maximum of 10 trials (2656 patients) provided paired data on exercise capacity and either 
mortality, hospitalisation, or HRQoL. This has a number of implications for the interpretation 
of our findings: (1) the statistical power of our analysis was low; evidenced by the wide 
confidence intervals in pooled analysis and whilst all outcomes were in direction of benefit of 
ExCR, none reached a level of formal statistical significance at 5% level, (2) and relatedly, 
we had limited statistical power to detect an association between changes in exercise capacity 
and the final patient-related outcomes, and (3) the results are likely to be subject to selection 
bias and therefore may not be representative of all RCT evidence. 
 
Relevance to clinical practice 
The observed improvements in patient exercise capacity and HRQoL with ExCR 
participation support the Class I recommendation of current international clinical guidelines 
that ExCR should be offered to HF patients. (3, 13, 15) Our findings do not endorse limiting 
ExCR interventions to subgroups of HF patients.  
Research recommendations  
1. In spite of the comprehensiveness of this IPD meta-analysis, findings of this study 
demonstrate that further evidence is still required to definitively assess the impact of 
ExCR on mortality and hospitalisation in patients with reduced ejection fraction HF; 
in particular, to increase the power to examine whether the effect of ExCR varies 
according to patient characteristics. To more reliably quantify the impact of ExCR on 
clinical outcomes and examine how these effects may vary across HF patients, there is 
an urgent need for trial investigators to more consistently collect, report, and share 
patient-level data in the future.  
Two central aspects of future data collection include a consensus on the definition, 
collection, and reporting of clinical event data, especially hospitalisation, plus the 
capture of data on patient level adherence to the amount of exercise training during 
the ExCR intervention period. More generally, the research community should 
continue to implement policies that encourage primary study authors to make their 
datasets available, either by depositing in publicly available repositories or shared 
with IPD meta-analysis collaborations when directly requested. (81) 
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2. Given the vast majority of IPD in this study was from HFrEF patients, future trials 
including HFpEF patients are needed to assess the effectiveness of ExCR and whether 
there are differential effects of ExCR in this patient group. 
3. Future IPD meta-analyses of RCTs for interventions in HF are needed to confirm the 
tentative conclusion that VO2peak and 6MWT may be suitable surrogate endpoints 
for the final patient-related outcomes. Such future IPD meta-analyses also need to 
consider individual patient adherence to exercise training.  
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Appendices 
Appendix 1: Project committees 
Project Management Group 
Professor Rod S Taylor (Chair), Institute of Health Research, University of Exeter Medical 
School, Exeter, UK 
 
Dr Oriana Ciani, Institute of Health Research, University of Exeter Medical School, Exeter, 
UK and Centre for Research on Health and Social Care Management, Bocconi University, 
Milan, Italy 
 
Associate Professor Constantinos H Davos, Cardiovascular Research Laboratory, Biomedical  
Research Foundation, Academy of Athens, Athens, Greece 
 
Professor Massimo Piepoli, Cardiology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy 
 
Professor Neil A Smart, University of New England, Armidale, Australia 
 
Dr Sarah Walker, Institute of Health Research, University of Exeter Medical School, Exeter, 
UK 
 
Dr Fiona C Warren, Institute of Health Research, University of Exeter Medical School, 
Exeter, UK 
 
 
International Steering Committee  
All members of the Project Management Group details above, plus: 
 
Professor Andrew Coats (Chair), IRCCS, San Raffaele, Pisana, Italy and University of 
Warwick, UK 
 
Professor Stephen Ellis, Duke Clinical Research Institute, North Carolina, USA  
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Associate Professor Hasnain M Dalal, University of Exeter Medical School, Exeter, UK and 
Research, Development & Innovation, Royal Cornwall Hospital, UK 
 
Professor Steven Keteyian, Department of Medicine, Henry Ford Hospital, Detroit, 
Michigan, USA  
 
Professor Christopher O’Connor, Duke Clinical Research Institute, North Carolina, USA 
 
Professor David Whellan, Department of Medicine, Sidney Kimmel Medical College, 
Philadelphia, Pennsylvania, USA 
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Appendix 2: Example database search strategy from Cochrane 2014 review 
MEDLINE(R) Ovid 1946 to January Week 4 2013  
1. exp Myocardial Ischemia/  
2. (myocard$4 adj5 (ischaemi$2 or ischemi$2)).ti,ab.  
3. ((ischaemi$2 or ischemi$2) adj5 heart).ti,ab.  
4. exp Coronary Artery Bypass/  
5. coronary.ti,ab.  
6. exp Coronary Disease/  
7. exp Myocardial Revascularization/  
8. Myocardial Infarction/  
9. (myocard$5 adj5 infarct$5).ti,ab.  
10. (heart adj5 infarct$5).ti,ab.  
11. exp Angina Pectoris/  
12. angina.ti,ab.  
13. exp Heart Failure/  
14. (heart adj5 failure).ti,ab.  
15. (HFNEF or HFPEF or HFREF or "HF NEF" or "HF PEF" or "HF REF").ti,ab.  
16. or/1-15  
17. exp Heart Diseases/  
18. (heart adj5 disease$2).ti,ab.  
19. myocard$5.ti,ab.  
20. cardiac$2.ti,ab.  
21. CABG.ti,ab.  
22. PTCA.ti,ab.  
23. (stent$4 and (heart or cardiac$4)).ti,ab.  
24. Heart Bypass, Left/ or exp Heart Bypass, Right/  
25. or/17-24  
26. *Rehabilitation Centers/  
27. exp Exercise Therapy/  
28. *Rehabilitation/  
29. exp Sports/  
30. Physical Exertion/ or exertion.ti,ab.  
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31. exp Exercise/  
32. rehabilitat$5.ti,ab.  
33. (physical$4 adj5 (fit or fitness or train$5 or therap$5 or activit$5)).ti,ab.  
34. (train$5 adj5 (strength$3 or aerobic or exercise$4)).ti,ab.  
35. ((exercise$4 or fitness) adj5 (treatment or intervent$4 or programs$2 or therapy)).ti,ab.  
36. Patient Education as Topic/  
37. (patient$2 adj5 educat$4).ti,ab.  
38. ((lifestyle or life-style) adj5 (intervent$5 or program$2 or treatment$2)).ti,ab.  
39. *Self Care/  
40. (self adj5 (manage$5 or care or motivate$5)).ti,ab.  
41. *Ambulatory Care/  
42. exp Psychotherapy/  
43. psychotherap$2.ti,ab.  
44. (psycholog$5 adj5 intervent$5).ti,ab.  
45. relax$6.ti,ab.  
46. exp Relaxation Therapy/ or exp Mind-Body Therapies/  
47. exp Counseling/  
48. (counselling or counseling).ti,ab.  
49. exp Cognitive Therapy/  
50. exp Behavior Therapy/  
51. ((behavior$4 or behaviour$4) adj5 (modify or modificat$4 or therap$2 or 
change)).ti,ab.  
52. *Stress, Psychological/  
53. (stress adj5 management).ti,ab.  
54. (cognitive adj5 therap$2).ti,ab.  
55. meditat$4.ti,ab.  
56. *Meditation/  
57. exp Anxiety/  
58. (manage$5 adj5 (anxiety or depress$5)).ti,ab.  
59. CBT.ti,ab.  
60. hypnotherap$5.ti,ab.  
61. (goal adj5 setting).ti,ab.  
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62. (goal$2 adj5 setting).ti,ab.  
63. (psycho-educat$5 or psychoeducat$5).ti,ab.  
64. (motivat$5 adj5 (intervention or interv$3)).ti,ab.  
65. Psychopathology/  
66. psychopathol$4.ti,ab.  
67. psychosocial$4.ti,ab.  
68. distress$4.ti,ab.  
69. exp Health Education/  
70. (health adj5 education).ti,ab.  
71. (heart adj5 manual).ti,ab.  
72. Autogenic Training/ 
73. autogenic$5.ti,ab.  
74. or/26-39  
75. or/40-73  
76. 16 or 25  
77. 74 or 75  
78. 76 and 77  
79. randomized controlled trial/  
80. randomized controlled trial.pt.  
81. controlled clinical trial.pt.  
82. controlled clinical trial/  
83. Random Allocation/  
84. Double-Blind Method/  
85. single-blind method/  
86. (random$ or placebo$).ti,ab.  
87. ((singl$3 or doubl$3 or tripl$3 or trebl$3) adj5 (blind$3 or mask$3)).ti,ab.  
88. exp Research Design/  
89. Clinical Trial.pt.  
90. exp clinical trial/  
91. (clinic$3 adj trial$2).ti,ab.  
92. or/79-91  
93. 78 and 92  
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94. (Animals not Humans).sh.  
95. 93 not 94  
96. limit 95 to yr="2008 -Current" 
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Appendix 3:  Identified randomised controlled trials meeting inclusion criteria 
First author (year)  
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Cochrane 2014 review 
Austin (2005/8)  200  Single II/III  NR  72  43  Mix  120  2.5  24  Both  60  
Belardinelli (1999)  99  Single II/IV  28  55  89  Aerobic  40  2.5  56  Centre  26  
Belardinelli (2012)  123  Single  II/III  37  59  78  Aerobic  40  2.5  56  Centre  120  
Davidson (2010)  105  Single  I/II/III/I
V  
.NR  72.3  67  Mix  40  1  12  Centre  12  
Dracup (2007)  173  Single  II/IV  26  54  72  Mix  28  4  52  Home  12  
DANREHAB (2008)  91  Single  I/II/III  NR  66  90  Mix  90  3  12  Both  12  
Gary (2010)  65  Single  II/III  NR  65.8  42  Aerobic  37.5  3  12  Home  6  
Giannuzzi (2003)  90  Multi II/III  25  60.5  .  Aerobic  30  4  24  Both  6  
Hambrecht (2000)  73  Single  I/II/III  29  54  100  Aerobic  15  6.5  24  Both  6  
HF-ACTION (2009)  2331  Multi II/III/IV  25  59  72  Aerobic  30  2.5  120  Both  48  
Jolly (2009)  169  Multi  I/II/IV  NR  66  75  Mix  25  5  48  Home  12  
Klecha (2007)  50  Single  II/III  28  61  100  Aerobic  20  3  24  Centre  6  
McKelvie (2002)  181  Multi I/II/III  NR  65.5  81  Mix  30  2  36  Both  12  
Mueller (2007)  50  Single  NR  NR  55  100  Aerobic  120  5  4  Centre  74  
Nilsson (2008)  80  Single  II/III  31  70  79  Aerobic  50  2  16  Centre  12  
Passino (2006)  95  Single  I/II/III  34  60.5  87  Aerobic  30  3  36  Home  9  
Willenheimer (2000)  54  Single  NR  36.5  64  71.5  Aerobic  30  2.5  16  Centre  10  
Witham (2005)  82  Single  II/III  NR  80.5  55  Mix  20  2.5  24  Both  6  
Witham (2012)  107  Single  II/III  NR  81  100  Mix  60  2  24  Both  6  
Yeh (2011)  100  Multi I/II/III  29  67.5  64  Aerobic  30  2.5  12  Both  6  
ExTraMATCH I (2004)  
Dubach (1997)/  
Meyers (2002)  
51  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  8.5  
Zanelli (1997)  155  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  10  
Wielenga (1999)  80  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  47.3  
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(1) Total number of patients randomised; (2) ‘Mix’ includes aerobic and resistance training; (3) Whether exercise setting is home or centre or both; 
NR: not reported in either Cochrane (2014) or ExTraMATCH I (2004) reports; NHYA: New York Heart Association 
Table reproduced from ExTraMATCH II Study Protocol: Taylor RS, Piepoli MF, Smart N, Coats AJS, Ellis S, Dalal H, O’Connor CM, Warren 
FC, Whellan D, Ciani O, and ExTraMATCH II Collaborators Exercise training for chronic heart failure (ExTraMATCH II): Protocol for an 
individual participant data meta-analysis. Int J Cardiol. 2014;174:683-7 
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Appendix 4: ExTraMATCH II core data fields 
Variable 
Description 
Study level data  
Centre ID  Centre name  
Randomised control patients (N)   
Randomised exercise patients (N)   
Patient level data – descriptive  
Patient ID   
Date of randomisation  dd/mm/yyyy  
Allocated treatment  1 Exercise  
2 Control  
Date of birth  dd/mm/yyyy  
Gender  1 Male  
2 Female  
9 Data unavailable  
Race  1 White/Caucasian  
2 African/African-American  
3 Asian  
4 Other  
9 Data unavailable  
Aetiology of heart failure  1 Ischaemic heart disease  
2 Idiopathic dilated cardiomyopathy  
3 Other/Unknown  
9 Data unavailable  
Year of heart failure diagnosis  yyyy  
New York Heart Association class at 
entry/baseline  
1 NYHA Class I  
2 NYHA Class II  
3 NYHA Class III  
4 NYHA Class IV  
9 Unknown/Unavailable  
Ejection fraction at entry/baseline (%)   
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Patient level data - Outcomes  
Method of exercise capacity assessment  1 6-minute walk test  
2 Bicycle ergometer test  
3 Treadmill test  
4 Other [state]  
Exercise capacity score at entry (units)   
Follow-up 1 exercise capacity score  Follow-up time (months)  
Follow-up 2 exercise capacity score  Follow up time (months)  
Follow-up 3 exercise capacity score  Follow up time([months)  
Health related quality of life  1 Minnesota Living With Heart Failure  
2 Other measure (state)  
HRQoL at entry  Total & subscores  
Follow-up 1 HRQoL score  Total & subscores  
Follow up time (months)  
Follow-up 2 HRQoL score  Total & subscores  
Follow up time (months)  
Follow-up 3 HRQoL score  Total & subscores  
Follow up time (months)  
Date of death  dd/mm/yyyy  
Cause of death  
 
1 Acute myocardial infarction  
2 Sudden death  
3 Heart failure  
4 Other cardiac  
5 Stroke  
6 Other vascular/thrombo-embolic  
7 Non-cardiovascular  
8 Unknown  
[1–4, cardiac; 1–6, cardiovascular]  
Date of first all-cause hospital admission  dd/mm/yyyy  
1 de novo hospitalisation  
2 rehospitalisation  
Date of first HF hospital admission  dd/mm/yy  
1 de novo hospitalisation  
2 rehospitalisation  
Number of all-cause hospitalisations   
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Number of all HF hospitalisations   
Drop-out  
Date of study discontinuation  dd/mm/yyyy  
Reason for study discontinuation  
 
Exercise training (only applies to exercise group patients)  
Study level data  
Prescribed exercise training  
Overall duration  
Session duration  
Frequency of sessions  
Intensity  
--- weeks (ranges if appropriate)  
---- minutes (range if appropriate)  
--- sessions/week (range if appropriate)  
----% units (range if appropriate)  
Setting  1 Centre only  
2 Home only  
3 Both centre and home (define proportion of 
sessions at each location)  
4 Other (state)  
Patient level data  
Attended first exercise training  1 Yes  
2 No  
3 Not reported  
Are details available at patient level on 
exercise dose received?  
1 Yes  
2 No  
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Appendix 5: Prediction of VO2peak in HF from submaximal exercise tests 
 
1: 6-minute walk test (6MWT) 
A number of studies have examined the relationship of 6MWT and VO2peak in HF patients 
and reported variable levels of association/correlation. Many studies failed to report a 
prediction equation or reported a multivariate equation that incorporated clinical parameters 
not available in the EMII IPD set. A recent discussion paper on the use of the 6MWT in HF, 
has questioned the reliability of prediction of VO2peak (42). However, a review in 2010 by 
Ross et al of 11 studies in 1,083 patients with cardiopulmonary disease (many with HF) 
found generally high level of association of VO2peak and 6MWT (average correlation 
coefficient of 0.59). (39) Using a study level random effects linear regression approach the 
authors derived the following overall prediction model with standard error of estimate (SEE) 
of 1.1 ml/kg/min. 
 
VO2peak (ml/kg/min) = 4.948 + 0.023 x 6-MWD distance (metres) 
 
2: Incremental shuttle walk test (ISWT) 
Keell et al (40) tested the safety and acceptability of the SWT in patients with chronic heart 
failure and examined the relationship between SWT performance and VO2peak.  
VO2peak (ml/kg/min) = (0·27 x number of 10m shuttles) + 7·77 
 
Similarly, Fowler et al (41) (41) proposed the following formula in patients following 
coronary artery bypass surgery: 
VO2peak (ml/kg/min) = 7.81 + [0.03 × ISWT distance (m)]  
 
 
